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ABSTRACT 
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by pain, 
chronic inflammation and joint destruction. Epidemiological investigations in large population-
based cohorts have identified both genetic (such as HLA-DRB1 Shared epitope, SE) and 
environmental (such as smoking) risk factors for the development of RA. One of the hallmarks 
of the disease is the presence of antibodies against a large array of citrullinated proteins (anti 
citrullinated protein antibodies, ACPA), which are present years before the onset of clinical 
symptoms. These findings suggest that RA-associated autoimmunity might be initiated 
somewhere else than the joints, possibly at the mucosal surfaces of the lungs. In the current 
thesis we aimed to investigate immunological events in the lungs contributing to ACPA 
generation and to identify novel targets for these antibodies.   
Presence of ACPA associates with parenchymal lung abnormalities (as detected by high 
resolution computed tomography, HRCT) in early-untreated RA. Recognition of more than one 
citrullinated target by ACPA and specifically recognition of citrullinated fibrinogen peptides 
increases the odds of detecting HRCT lung abnormalities. Beside HRCT abnormalities, 
significantly decreased microbial richness and diversity is present in the bronchoalveolar 
lavage of early-untreated RA patients as compared to healthy volunteers. Interestingly, a 
similar microbiota dysbiosis is also detected in the presence of overt lung inflammation in the 
bronchoalveolar lavage of patients with lung sarcoidosis, suggesting that similar inflammatory 
mechanisms might be active in both lung sarcoidosis and RA.  To further explore the possibility 
that changes in the lungs contribute to generation of autoimmunity in RA, we investigated the 
presence of citrullinated targets in the mucosal biopsies of early-untreated RA. We identified 
several novel citrullinated targets, with two citrullinated vimentin peptides detected in a 
majority of the biopsies. Interestingly these two peptides were also identified in the inflamed 
synovial tissues of RA patients showing that shared immunological targets are present in the 
lungs and joints in RA patients. Antibodies against these novel targets were detectable in RA 
patients suggesting that they could act as immunological targets during disease development. 
Using a similar approach, we further screened for antibody-reactivity against novel citrullinated 
targets identified in the synovial fluid of RA patients. Several citrullinated fibrinogen peptides 
specifically reacted with the antibodies in RA serum, with varying proportion of reactivity for 
each of these peptides. Interestingly, these antibodies differ from the classical ACPA being 
associated with the PTPN22 risk allele but not with the HLA-DRB1 SE. As such RA patients 
carrying the PTPN22 risk allele displayed higher proportion of B cells reacting with 
citrullinated fibrinogen loaded B cell antigen tetramers than those lacking the risk allele.  
In conclusion, we provide evidence for a pathogenic link between early events in the 
lungs and autoimmunity in RA and identify several novel immunological targets for this 
autoimmunity. Our studies contribute to the understanding of the longitudinal development of 
RA, opening the possibility for future targeting of early pathogenic events in order to delay 
and/or prevent the disease.  
  
LIST OF SCIENTIFIC PAPERS 
 
  I. Association between number and type of different ACPA fine specificities 
with lung abnormalities in early, untreated rheumatoid arthritis. 
Vijay Joshua, Aase Haj Hensvold, Gudrun Reynisdottir, Monika Hansson, 
Martin Cornillet, Leonor Nogueira, Guy Serre, Sven Nyren, Reza Karimi, Anders 
Eklund, Carl Magnus Sköld, Johan Grunewald, Katerina Chatzidionysiou* and 
Anca I. Catrina*.  
Submitted. * Contributed Equally 
 
 
 
II. The lung microbiota in early rheumatoid arthritis and autoimmunity. 
Jose U. Scher, Vijay Joshua, Alejandro Artacho, Shahla Abdollahi-Roodsaz, 
Johan Öckinger, Susanna Kullberg, Magnus Sköld, Anders Eklund, Johan 
Grunewald, Jose C. Clemente, Carles Ubeda, Leopoldo N. Segal and Anca I. 
Catrina. 
Microbiome, 2016, 4(1):60. 
III. Shared immunological targets in the lungs and joints of patients with 
rheumatoid arthritis: identification and validation. 
A Jimmy Ytterberg, Vijay Joshua, Gudrun Reynisdottir, Nataliya K Tarasova, 
Dorothea Rutishauser, Elena Ossipova, Aase Haj Hensvold, Anders Eklund, C 
Magnus Sköld, Johan Grunewald, Vivianne Malmström, Per Johan Jakobsson, 
Johan Rönnelid, Leonid Padyukov, Roman A Zubarev, Lars Klareskog and Anca 
I Catrina. 
Annals of Rheumatic Diseases, 2015 Sep, 74(9):1772-7. 
 
 
 
IV. Antibody responses to de novo identified citrullinated fibrinogen peptides in 
rheumatoid arthritis and visualization of the corresponding B cells. 
Vijay Joshua, Loes Schobers, Philip J. Titcombe, Lena Israelsson, Johan 
Rönnelid, Monika Hansson, Anca I. Catrina, Ger J. M. Pruijn and Vivianne 
Malmström.  
Arthritis Research & Therapy, 2016, 18(1): 284. 
 
RELATED SCIENTIFIC PAPERS NOT INCLUDED IN THE 
THESIS 
 
V. Mechanisms involved in triggering rheumatoid arthritis.  
Anca I. Catrina, Vijay Joshua, Lars Klareskog and Vivianne Malmström.  
Immunological Reviews, 2016 Jan, 269(1):162-74. 
 
 
VI. Identification of a novel chemokine-dependent molecular mechanism 
underlying rheumatoid arthritis-associated autoantibody-mediated bone 
loss. 
Akilan Krishnamurthy, Vijay Joshua, Aase Haj Hensvold, Tao Jin, Meng Sun, 
Nancy Vivar, A Jimmy Ytterberg, Marianne Engström, Catia Fernandes-
Cerqueira, Khaled Amara, Malin Magnusson, Gustaf Wigerblad, Jungo Kato, 
Juan Miguel Jiménez-Andrade, Kerry Tyson, Setphen Rapecki, Karin Lundberg, 
Sergiu-Bogdan Catrina, Per-Johan Jakobsson, Camilla Svensson, Vivianne 
Malmström, Lars Klareskog, Heidi Wähämaa and Anca I. Catrina. Annals of 
Rheumatic Diseases, 2016 Apr, 75(4):721-9. Epub 2015 Nov 26 
 
 
VII. Signs of immune activation and local inflammation are present in the 
bronchial tissue of patients with untreated early rheumatoid arthritis. 
Gudrun Reynisdottir, Helga Olsen, Vijay Joshua, Marianne Engström, Helena 
Forsslund, Reza Karimi, Carl Magnus Sköld, Sven Nyren, Anders Eklund, Johan 
Grunewald and Anca I. Catrina.  
Annals of Rheumatic Diseases, 2016 Sep, 75(9):1722-7. Epub 2015 Nov 3 
 
 
VIII. Serum RANKL levels associate with anti- citrullinated protein antibodies in 
early untreated rheumatoid arthritis and are modulated following 
methotrexate. 
Aase Haj Hensvold, Vijay Joshua, Wanying Li, Michaela Larkin, Ferhan 
Qureshi, Lena Israelsson, Leonid Padyukov, Karin Lundberg, Nadine Defranoux, 
Saedis Saevarsdottir and Anca I. Catrina.  
Arthritis Research & Therapy, 2015 Sep, 17:239 
 
 
IX. Structural changes and antibody enrichment in the lungs are early features 
of anti-citrullinated protein antibody-positive rheumatoid arthritis. 
Gudrun Reynisdottir, Reza Karimi, Vijay Joshua, Helga Olsen, Aase Haj 
Hensvold, Anders Harju, Marianne Engström, Johan Grunewald, Sven Nyren, 
Anders Eklund, Lars Klareskog, Carl Magnus Sköld and Anca I. Catrina.  
Arthritis & Rheumatology, 2014 Jan, 66(1):31-9. 
 
  
X. Environmental and genetic factors in the development of anticitrullinated 
protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an 
epidemiological investigation in twins. 
Aase Haj Hensvold, Patrik K. Magnusson, Vijay Joshua, Monika Hansson, Lena 
Israelsson, Ricardo Ferreira, Per-Johan Jakobsson, Rikard Holmdahl, Lennart 
Hammarström, Vivianne Malmström, Johan Askling, Lars Klareskog and Anca I. 
Catrina.  
Annals of Rheumatic Diseases, 2015 Feb, 74(2):375-80. Epub 2013 Nov 25 
 
 
XI. Monoclonal IgG antibodies generated from joint-derived B cells of RA 
patients have a strong bias toward citrullinated autoantigen recognition. 
Khaled Amara, Johanna Steen, Fiona Murray, Henner Morbach, Blanca M. 
Fernandez-Rodriguez, Vijay Joshua, Marianne Engström, Omri Snir, Lena 
Israelsson, Anca I. Catrina, Hedda Wardemann, Davide Corti, Eric Meffre, Lars 
Klareskog and Vivianne Malmström.  
The Journal of Experimental Medicine, 2013 Mar, 210(3):445-55. Epub 2013 Feb 
25. 
 
  
 
 
  
CONTENTS 
1 Introduction .......................................................................................................... 1 
1.1 Rheumatoid Arthritis ................................................................................... 1 
1.2 Historical description and classification of RA .......................................... 1 
1.3 Genetic risk Factors associated with RA .................................................... 2 
1.4 Environmental risk Factors associated with RA ......................................... 3 
1.5 Posttranslational Modifications in RA ........................................................ 4 
1.5.1 Citrullination ................................................................................... 4 
1.5.2 Carbamylation ................................................................................. 5 
1.5.3 Acetylation ...................................................................................... 6 
1.5.4 Malondialdehyde Modification ....................................................... 6 
1.6 Autoantibodies in RA .................................................................................. 7 
1.6.1 Rheumatoid Factor .......................................................................... 7 
1.6.2 Anti-citrulline protein antibodies .................................................... 7 
1.7 Effector Functions of autoantibodies in RA ............................................... 8 
1.8 Role of Lungs in RA ................................................................................. 10 
1.9 Microbiome in RA .................................................................................... 12 
1.9.1 Methods to study microbiome ...................................................... 12 
1.9.2 The Gut Microbiome ..................................................................... 13 
1.9.3 The Oral Microbiome .................................................................... 14 
1.9.4 The Lung Microbiome .................................................................. 15 
1.10 Model for etiology and pathogenesis of RA ............................................. 16 
2 Aims ................................................................................................................... 19 
3 Materials and Methods ....................................................................................... 21 
3.1 Subjects ...................................................................................................... 21 
3.1.1 LURA Cohort (Paper I, II, III) ...................................................... 21 
3.1.2 RA Cohort (Paper II, IV) .............................................................. 22 
3.1.3 Disease Controls (Paper II, III, IV) ............................................... 22 
3.1.4 Healthy Controls (Paper I, II, III, IV) ........................................... 23 
3.2 High Resolution Computed Tomography and Spirometry (Paper I) ....... 23 
3.3 HLA-DR and PTPN22 Genotyping (Paper I, III, IV) .............................. 24 
3.4 Microbiome Analysis (Paper II) ............................................................... 24 
3.4.1 DNA Extraction and Sequencing .................................................. 24 
3.4.2 Microbiome sequence Analysis .................................................... 24 
3.5 Mass Spectrometry (Paper III) .................................................................. 24 
3.6 Detection and Measurement of Autoantibodies ....................................... 25 
3.6.1 Multiplex peptide chip-based assay (Paper I, II) .......................... 25 
3.6.2 In-house Enzyme-Linked Immunosorbent Assay (Paper III, IV) 26 
3.7 Tetramer Production and Flow cytometry (Paper IV) .............................. 27 
3.8 Statistical Analysis .................................................................................... 28 
4 Results and discussion ....................................................................................... 29 
4.1 Signs of Immune activation and inflammation are present in the lungs of 
early untreated RA ..................................................................................... 29 
4.2 HRCT Parenchymal lung abnormalities are associated with increased in 
ACPA fine specificities in early untreated RA ......................................... 30 
4.3 Distal airway dysbiosis is present in the early untreated RA ................... 32 
4.4 Shared immunological targets are present in the lungs and joints of RA 35 
4.5 Systemic response to de novo identified citrullinated fibrinogen is 
associated with PTPN22 risk allele. .......................................................... 38 
5 Conclusion and Future Perspectives .................................................................. 41 
6 Acknowledgements ............................................................................................ 43 
7 References .......................................................................................................... 47 
 
  
  
LIST OF ABBREVIATIONS 
ACPA Anti-citrulline protein antibodies 
ACR American college of rheumatology 
AKA Anti-keratin antibodies 
APF Antiperinuclear factor 
ARA American rheumatology association 
BAL  Brohchoalveolar lavage 
BCR B cell receptor 
CarP Carbamylated proteins 
CCP Cyclic citrullinated peptide 
CII Collagen type II 
Cit Citrullinated 
CTLA4  Cytotoxic T lymphocyte-associated protein 4 
EULAR European League Against Rheumatism 
Grp78 Citrullinated glucose-regulated protein 78 
HLA Human leucocyte antigen 
HRCT High resolution computed tomography 
iBALT Inducible bronchus-associated lymphoid tissue 
Ig Immunogloublin 
ILD Interstitial lung disease  
Lyp Lymphoid phosphatase 
MDA Malondialdehyde  
OA Osteoarthritis  
OTU Operational taxonomic unit 
PAD Peptidyl arginine deiminase  
PADI4  Peptidyl arginine deiminase 4 gene 
PTPN22 Protein tyrosine phosphatase non-receptor type 22 
RA Rheumatoid arthritis 
ReA Reactive arthritis  
RF Rheumatoid factor 
rRNA Ribosomal ribonucleic acid 
SCFA Short chain fatty acids 
SE Shared epitope 
SNP Single neuclotide polymorphism 
STAT4  Signal transducer and activator of transcription 4 
T1D Type 1 diabetes 
TCR T cell receptor 
TNF Tumor necrosis factor  
TRAF1 TNF receptor-associated factor 1 
 
  1 
1 INTRODUCTION 
1.1  Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a chronic systemic inflammatory autoimmune disease 
affecting the joints which when left untreated leads to joint erosions, destruction and 
deformities of the joints. RA affects 0.5-1% of the world population [1]. It predominantly 
affects females rather than males, in the ratio of 3:1 [2]. The disease in its pathological state is 
characterized by inflamed synovium, accumulation of synovial fluid and destruction of the 
cartilage and bone. 
 
1.2  Historical description and classification of RA 
Paleontological data from skeletons obtained from sites in ancient Egypt, Greece and the 
Nordics have demonstrated the presence of bone lesions and joint deformities that are 
indicative of RA [3]. This has given rise to speculation of RA being a disease since ancient 
times. Evidences of RA can also be found in the art such ‘The Painter’s Family’ by Flemish 
painter Jacob Jordaens (1593–1678), ‘Saint Matthew’ (1609), ‘The Drunken Sleeping Satyr’ 
(1610), ‘Suzanna and the Elders’ (1614) and ‘Between Christ and the Virgin’ by Flemish 
painter Peter Paul Rubens, ‘The Sleeping Cupid’ (1608) by Italian painter Michelangelo 
Caravaggio and many others [4]. 
The first description of RA acknowledged by modern medicine was by the French 
surgeon Augustin Jacob Landré Beauvais in his dissertation during 1800. The term 
‘Rheumatoid arthritis’ was coined by the British physician Archibald Garrod in 1890 [3]. Many 
efforts have been made to classify the disease and the first classification criteria were proposed 
by the American Rheumatology Association (ARA) in 1957 which was later revised in 1958 
[5]. This was used in practice until 1987 when the revised classification criteria by the 
American College of Rheumatology (ACR) were formulated [6]. Since the 1987 criteria for 
RA are fulfilled rather late in the disease, a new criteria set was developed by ACR/European 
League Against Rheumatism (EULAR) in 2010 that allows the classification of RA very early 
in disease course [7]. The current criteria focus on the early disease and includes the presence 
of autoantibodies such as anti citrullinated protein antibodies (ACPA) and rheumatoid factor 
(RF). 
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1.3  Genetic risk Factors associated with RA 
Research conducted decades earlier found an association between the Human Leucocyte 
Antigen HLA-DRB1 and RA which lead to the ‘Shared Epitope’ (SE) hypothesis for genetic 
susceptibility in RA [8]. The HLA-DRB1 gene encodes the beta chain of the HLA class II 
molecule which along with the alpha chain is involved in antigen presentation to the T cells. 
The susceptibility is conferred by the amino acids present in position 11, 71 and 74 that are 
involved in the peptide binding grove of the HLA molecule. The HLA-DRB1 allele that are 
considered SE include *01:01, *01:02, *04:01, *04:04, *04:05, *04:08, and *10:01 [9]. 
Structural analysis has shown that citrullinated peptides (which are autoantigens in RA) 
preferentially bind to the P4 pocket in the peptide binding grove of the HLA-DR SE compared 
to the native peptides [10]. Epidemiological studies have found a strong association between 
the HLA-DRB1 SE and development of RA [11, 12] with the SE homozygotes having a higher 
risk to develop RA compared to heterozygotes having odds ratios of 2.32 and 8.33 respectively 
[12]. 
The polymorphism of the Protein tyrosine phosphatase non-receptor type 22 (PTPN22) 
gene is another genetic risk for RA. PTPN22 C1858T (R620W) allele was first identified as 
a risk factor for type 1 diabetes (T1D) [13] and subsequent studies found the polymorphism 
to be a risk factor for RA [14]. The PTPN22 encodes the protein lymphoid phosphatase (Lyp) 
which is a class 1 protein tyrosine phosphatase and is involved in the downstream T cell 
receptor (TCR) and B cell receptor (BCR) signaling [15]. Early studies in human samples 
have proposed that the PTPN22 C1858T variant is a gain of function mutation resulting in 
enhanced inhibition of TCR signaling [16]. However, in two knock-in mouse models 
expressing the analogous mutation R619W, in the murine ortholog PEST domain 
phosphatase (PEP), enhanced TCR signaling was observed [17]. Similarly, mice lacking the 
PTPN22 gene have an enhanced TCR signaling against very weak antigens and self-antigens 
but very few differences in TCR signaling against strong antigens [18]. Due to contradictory 
conclusions from these studies, the exact role of this single nucleotide polymorphism (SNP) 
in T cells is yet to be clarified. Studies conducted in B cells with Lyp R620W from T1D 
shows an altered B cell homeostasis leading to expansion of transitional and anergic B cells 
and decreased BCR signaling [19]. Analysis of BCR in Healthy, T1D and RA individuals 
with PTPN22 C1858T have found and enhancement of autoreactive B cells in the periphery 
[20]. A study looking into a large cohort of RA patients found a very strong gene-gene 
interaction between HLA-DR SE and PTPN22 to develop ACPA positive RA having an odds 
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ratio of 13.2 compared to 6.1 and 1.4 with individuals carrying either HLA-DR SE or 
PTPN22 C1858T respectively [21]. 
Currently there are more than 100 genetic polymorphisms associated with RA [22] 
including STAT4 [23], TRAF1-C5 [24], PADI4 and CTLA4 [25]. 
 
1.4  Environmental risk Factors associated with RA 
Smoking is one of the best established environmental risk factors for RA, especially in 
ACPA positive RA [26, 27]. In a case-control study of 679 RA patients found that those that 
have smoked for over 20 years had a higher relative risk of 2.7 to develop ACPA positive/RF 
positive RA [28]. In smokers carrying one or two copies of the shared epitope risk allele, the 
relative risk of ACPA positive RA is 6.5 and 21.0 respectively, suggesting a complex 
interaction between genetic and environmental risk factors for the development of RA [11]. 
Another environmental risk factor for RA is exposure to silica in industries involving 
mining, construction, ceramics, glass and electronics. In a case-control study of 276 males with 
RA, those that were exposed to silica was found to have an odds ratio of 2.2 for developing 
RA, when adjusted for age, residential area and smoking [29]. In a subsequent study with 
increased sample size by the same authors found that current smokers exposed to silica were 
found to have a higher risk of developing RA with odds ratio of 7.36 when compared to never 
smokers unexposed to silica [30].  
Textile dust has been implicated as one of the environmental risk factors for RA. In a 
case-control study comparing Malaysian women with occupational exposure to textile dust 
found an odds ratio of 2.8 to develop RA [31]. The odds for RA was even higher for individuals 
carrying any shared epitope risk allele (OR 2.5 for non-carriers vs 25.1 for carriers), which is 
in agreement with the gene-environment interaction for development of RA. 
The exposure to air pollution assessed by outdoor levels of different size fractions of 
particulate matter (PM10 and PM2.5) and gaseous pollutants (SO2 and NO2) found no association 
for risk of RA in an American [32] or Swedish cohort [33]. However, another study where 
exposure to traffic pollution defined by distance to road (0–50, 50–200, ≥ 200 meters), after 
adjustment for age, calendar year, race, cigarette smoking, parity, lactation, menopausal status 
and hormone use, oral contraceptive use, body mass index, physical activity, and census-tract-
level median income and house value, an elevated risk of RA was observed for women living 
within 50 meters from road compared to those living farther away [34]. 
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1.5  Posttranslational Modifications in RA 
Many posttranslational modifications have been identified and implicated in the 
pathogenesis of RA. This section gives an overview of all known modification associated with 
RA and their role in the disease.  
1.5.1 Citrullination 
Citrulline is a non-coding amino acid formed by the deimination of peptidyl arginine by 
the Peptidyl Arginine Deiminase (PAD) enzymes. The process converts the positively charged 
arginine into a neutrally charged citrulline residue creating a minor mass shift of approximately 
1 Da (figure 1). The PAD enzymes catalyze this process under high calcium (Ca2+) 
concentrations and human PAD cannot convert free arginine to citrulline. There are five known 
isoforms of this enzyme in humans namely PAD1, PAD2, PAD3, PAD4 and PAD6. PAD1 is 
found in the epidermis and uterus, PAD2 in skeletal muscles, brain, inflammatory cells, 
secretory glands, PAD3 in hair follicles and keratinocytes, PAD4 in granulocytes and PAD6 in 
oocytes and embryos [35]. Interestingly, the only know bacterial PAD enzyme known as PPAD 
is found in Porphyromonas gingivalis which is one of the pathogens causing Periodontitis [36]. 
Citrullination is found under normal physiological conditions in the terminal 
differentiation of keratinocytes which facilitates crosslinking, creating a matrix resistant to 
insults [37]. Upon challenge neutrophils release neutrophil extracellular traps (NETs) which 
contain deiminated histone H3, to entrap extracellular pathogens  [38]. Analysis of different 
human inflammatory and non-inflammatory tissues by immunohistochemistry has shown that 
citrullination is an inflammation-dependent process [39]. Analysis of bronchoalveolar lavage 
(BAL) cells from healthy smokers and non-smokers has shown that higher expression of PAD2 
and citrullination are present in smokers [40], suggesting that environmental factors such as 
smoking could play a role in triggering citrullination in the lungs. 
Citrulline as a constituent autoantigen in RA arises from exploring the targets of 
antiperinuclear factor (APF) and anti-keratin antibodies (AKA), which were one of the earliest 
assays used to identify autoantibodies in RA [41, 42]. The targets of AKA and APF were found 
to be filaggrin containing citrulline residues. Presence of citrullination is not restricted to RA 
but also found in osteoarthritis (OA) and reactive arthritis (ReA) synovium, as shown by 
immunohistological analysis [43]. Analysis of bronchial biopsies have shown that citrullination 
is enhanced in the lungs of ACPA positive RA smokers as compared to ACPA negative RA 
[44]. In a study comparing synovial biopsies from healthy volunteers and RA patients before 
and after treatment with glucocorticoids and methotrexate found that, citrullination was 
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enhanced in the RA synovium and decreased after treatment with glucocorticoids but not 
methotrexate [45]. This shows that treatment affecting inflammation could also bring down 
citrullination in RA. Citrulline immunity in RA gives rise to ACPAs whose role and function 
will be discussed in detail later. 
 
Figure 1: Different post translational modifications in RA. The figure represents the 
structural similarities between the different post translational modifications in RA. The homo-
citrulline has one more carbon atom in the backbone compared to citrulline, whereas the 
acetyllysine has a CH3 compared to NH2 in its side chain compared to homo-citrulline. 
 
1.5.2 Carbamylation 
Carbamylation is the non-enzymatic post translational modification of proteins with the 
addition of cyanate to primary amino- or thiol groups. One of the common carbamylation 
reactions is the conversion of lysine to homocitrulline [46] which resembles the peptidyl-
citrulline but is one CH2 group longer (figure 1). Carbamylation decreases the activity of 
enzymes and hormones such as ceruloplasmin, apo-aspartate aminotransferase, matrix 
metalloproteinase-2, erythropoietin, human serum albumin and insulin [47]. The carbamylation 
equilibrium is disrupted during disease condition. Patients suffering from uremia have an 
increased level of carbamylation but the contribution of carbamylation to the disease condition 
is difficult to ascertain and is not understood. The antigenicity towards carbamylated proteins 
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was evaluated by measuring antibodies against carbamylated antigens in the serum of RA and 
it was found that 45% of the RA serum contained antibodies against carbamylated proteins 
(CarP) [48]. Subsequently, autoantibody-reactivity against carbamylated alpha enolase [49] 
and fibrinogen [50] were present in most of the ACPA positive individuals but also detected in 
some serum samples of the ACPA negative individuals. This reactivity was predominantly 
overlapping with anti citrulline reactivity, with 37% being both anti citrulline and anti 
carbamylation positive and 8% being only anti carbamylation positive. Studies using animal 
models have shown that immunization of mice with carbamylated antigens could active T cells, 
cause immune activation and arthritis, demonstrating its arthrogenic properties [51]. In a recent 
study in mice, elevated levels of carbamylated proteins and antibodies against carbamylated 
proteins were detected in the blood of animals exposed to cigarette smoking [52]. These results 
together highlight the importance of studying the immunity against carbamylation. 
 
1.5.3 Acetylation 
Recently, acetylation has been proposed as another immunogenic post translational 
modification in RA. Acetylation is a very common histone modification-process , carried out 
by the enzyme histone acetyltransferase whereby acetyl groups are added to the free amines of 
the lysine residues [53]. The structure of the acetylated lysine side chain closely resembles the 
carbamylated lysine except for the terminal amine (NH2) group replaced by a methyl (CH3) 
group (figure 1). Analysis of serum from early untreated RA patients, showed the presence of 
autoantibodies against acetylated vimentin. The reactivity against acetylated vimentin was 
confined to those that had reactivity towards citrullinated vimentin peptide, however cross 
reactivity assays using serum blocked by modified peptides displayed a lesser amount of cross 
reactivity between the different post translational modifications [54]. More studies are required 
to ascertain the immunogenicity of acetylation in RA. 
 
1.5.4 Malondialdehyde Modification 
Another modification that has been recently identified as immunogenic in RA is the 
Oxidation-associated malondialdehyde (MDA) [55]. MDA is a naturally occurring, highly 
reactive aldehyde, produced under oxidative stress states associated with excessive generation 
of reactive oxygen species (ROS). MDA modifications occur in amino acids such as lysine, 
arginine, and histidine and to a lesser extent asparagine and glutamine. Analysis of serum from 
patients demonstrated the presence of high titers of anti-MDA antibodies in RA compared to 
other disease controls and healthy individuals. The same study, using mass spectrometry on 
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synovial biopsies, MDA modifications were identified in proteins such as actin, hemoglobin, 
serum albumin among others. In vitro stimulation of osteoclasts (bone resorbing cells) using 
anti-MDA antibodies enhanced their differentiation and bone resorption capacity [55]. 
 
1.6 Autoantibodies in RA 
Autoantibodies that have been identified in RA are RF, ACPA, anti-CarP antibodies, 
anti-MDA antibodies and anti-acetylated antibodies. Antibodies reacting against these different 
posttranslational modifications are known as anti-modified protein antibodies (AMPA) [56]. 
The most abundant of these are the RF and ACPA. 
 
1.6.1 Rheumatoid Factor 
Rheumatoid Factor (RF) are natural occurring autoantibodies against the Fc portion of 
IgG.  RF first described in 1940 [57] and were named so due to their association with RA [58].  
They are generally low affinity, poly-reactive antibodies of mainly IgM isotype, however IgA, 
IgG and IgE isotypes have been detected in serum of RA patients [59, 60]. IgG RF has been 
found in 70% of the RA patients but is not specific for the disease. The presence of RF has 
been reported in the healthy population, in disease conditions such as psoriatic arthritis, primary 
Sjögren’s syndrome, systemic lupus erythematosus, and also during bacterial and viral 
infections [61].  In a case-control study of blood donors, IgA RF was the earliest autoantibody 
to be detected before the disease onset and was a very good predictor of RA [62]. In a study 
analyzing the different RF isotypes and retrospective X rays in RA patients, found an 
association between IgA RF and periarticular bone erosion in the hands but not with IgG and 
IgM RF [63]. Extra-articular manifestations (vasculitis, rheumatoid nodules) were more 
frequent in RF positive, but not in ACPA positive, compared to negative patients [64]. 
 
1.6.2  Anti-citrulline protein antibodies 
ACPAs are antibodies that recognize antigens that contains the non-coding amino acid 
citrulline. The first ELISA to detect ACPA was developed using peptides derived from 
filaggrin, which has a sensitivity of 76% and specificity of 96% [42] and by using a cyclic 
variant of the peptide (CCP) gives a moderate sensitivity of 68% and an increased specificity 
of 98% [65]. Currently a second generation of this cyclic citrullinated peptides (CCP2), which 
has a better diagnostic and prognostic ability than CCP is being used commercially in detection 
of ACPAs [66]. ACPAs recognize citrullinated epitopes present on several proteins namely 
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filaggrin, fibrinogen [67], vimentin [68], alpha-enolase [69], collagen type II [70], Histone H4 
[71], tenascin-C [72], apolipoprotein E, myeloid nuclear differentiation antigen and β-actin 
[73]. ACPA in diagnostics is typically measured as IgG, however APCAs can be present as 
IgM, IgA, IgG1, IgG2, IgG3 and IgG4 isotypes [74]. Analysis of serum from patients with 
undifferentiated arthritis towards RA, revealed that although the number of isotypes did not 
change rapidly at follow up, the presence of more isotypes correlated with high levels of 
ACPAs and were significant predictors of radiographic progression [75]. 
Retrospective studies analyzing serum from blood donors have shown the presence of 
ACPAs as early as 10 years prior to the onset of the clinical symptoms of RA [62, 76]. The 
presence of ACPAs is associated with severe disease course and radiological progression [77]. 
In a study of 242 patients with RA, it was observed that the prevalence of joint erosions, 
assessed using high-resolution peripheral quantitative computer tomography (HR-pQCT) was 
more in the ACPA and RF positive group as compared to only ACPA or RF positive and RF 
negatives, suggesting an additive effect of both ACPA and RF in bone erosion in RA [78]. The 
presence of ACPA against antigenic targets present in different proteins is termed as the ACPA 
fine specificity repertoire. In studies analyzing blood samples from individuals predating the 
disease, an increase in ACPA fine specificity was seen very close to onset of clinical RA [79, 
80]. This indicates a process of antibody maturation and epitope spreading leading to the 
disease onset. 
 
1.7  Effector Functions of autoantibodies in RA 
Over the years, studies have been carried out to understand the effector functions of the 
autoantibodies in RA (figure 2). Earlier studies, using monoclonal antibodies against 
citrullinated fibrinogen injected into mice did not show development of arthritis, however when 
injected along with an ‘arthrogen’ (like antibodies against CII) significantly increased the 
severity of arthritis compared to mice injected with arthrogen alone or in combination with a 
control antibody [81]. This study demonstrates the ability of ACPA to enhance the disease and 
propagate inflammation. There are growing number of in vitro studies investigating the ACPA 
effects on different cell types. ACPA-containing immune complexes act on macrophages via 
the Fc gamma Receptor (FcγR) IIa to enhance the production of proinflammatory cytokines 
such as TNF [82]. Similar study using ACPA immune complexes containing citrullinated 
fibrinogen were able to stimulate macrophages via both the Toll-like receptor 4 (TLR-
4)/myeloid differentiation protein (MyD88) and the FcγR pathway to produce TNF [83]. 
Analysis of ACPA from RA serum showed that it can activate the complement system via the 
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classical and alternative pathway but not the lectin binding pathway [84]. Studies using U937 
cells (monocyte cell line) revealed that ACPA bound to surface-expressed citrullinated 
glucose-regulated protein 78 (Grp78) enhanced the production of TNF [85]. This mechanism 
was mediated through the ERK1/2 and JNK signaling pathways to enhance IKK-α 
phosphorylation, which leads to the activation of NF-κB and the production of TNF [86]. These 
studies highlight the role of ACPA in promoting inflammation in- and outside the joint in RA. 
Studies comparing polyreactive (low affinity) and monoreactive (high affinity) IgM RF 
derived from RA patients have shown that the monoreactive IgM RF has a higher complement 
activating capacity [87]. In a study using IgM RF derived from a patient with type II 
cryoglobulinemia, on monocyte derived macrophages found that, IgM RF by itself did not 
promote TNF secretion but together with ACPA-citrullinated fibrinogen immune complex 
(ACPA-IC) was able to enhance proinflammatory cytokine production by macrophages [88]. 
Similar results were observed using IgM and IgA RF derived from RA patients, where IgM 
and IgA RF in combination with ACPA-IC had different dose-dependent effects on 
macrophages [89]. 
Recent studies have focused on understanding the bone destruction-capacity of ACPA. 
Affinity purified antibodies against mutated citrullinated vimentin (MCV) were used to 
stimulate in vitro generated osteoclasts and found that anti-MCV antibodies enhanced both 
osteoclastogenesis and bone destruction. The authors showed that this was mediated by the 
antibodies binding to citrullinated vimentin on the surface of osteoclasts and downstream 
induction of TNF [90]. Similarly, ACPAs isolated from patients by affinity chromatography 
against CCP2, were used to study the effects on osteoclasts. The purified polyclonal ACPAs 
enhanced the osteoclast maturation and bone-destruction capacity [91]. Osteoclasts stimulated 
with monoclonal antibodies generated from single B cell cloning showed that only specific 
ACPAs could induce osteoclastogenesis. This mechanism of enhanced osteoclast activity was 
found to be dependent on the PAD enzymes and IL-8 in an autocrine manner.  Furthermore, 
intravenous injection of ACPAs in mice decreased trabecular bone mineral density compared 
to controls, which was reversed by subcutaneous administration of reparixin (IL-8 antagonist) 
[91]. Mice injected with ACPAs also exhibited long-lasting pronounced pain-like behavior in 
the absence of inflammation compared to control animals injected with non-ACPA IgGs. This 
pain like behavior was dependent on osteoclast-derived release of CXCL1/2 (Mouse IL-8 
analogue) which activates the sensory neurons through the receptor CXCR2 [92]. This could 
explain the arthralgia that commonly precedes the onset of synovitis in individuals who develop 
ACPA positive RA [93, 94]. 
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Figure 2: Functions of autoantibodies in RA. The figure summarizes the functional role of 
ACPA,RF and Immune complexes on different immune cells in the joints namely Osteoclasts, 
Macrophages, Neutrophils, and the role of other inflammatory mediators in the joints (adapted 
from [148]). 
 
1.8  Role of Lungs in RA 
The lungs are one of the primary organs that have been implicated as both the cause and 
consequence of RA. The lung involvement amongst extra-articular manifestations of RA is 
well documented. Studies have shown that lung disease such as pulmonary fibrosis is the 
second leading cause of mortality in RA [95]. There are a spectrum of lung manifestations in 
RA, that are classified as Airway disease (Cricoarytenoid arthritis, Emphysematous type, 
Bronchiolitis/obliterative bronchiolitis, Bronchiectasis), Parenchymal disease (Non-specific 
interstitial pneumonia, Usual interstitial pneumonia, Acute interstitial pneumonia/diffuse 
alveolar damage, Organizing pneumonia, Nodules including rheumatoid nodules and Caplan’s 
syndrome), Vascular disease (Rheumatoid vasculitis, Pulmonary hypertension, 
Thromboembolic disease), Pleural disease (Pleuritis/pleural thickening, Pleuropericardial 
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effusion, Bronchopleural fistula, Pneumothorax) and others (Medication/drug toxicity, 
Infection, Malignancy including pulmonary lymphoma) [96].  
A population-based study comparing RA patients and controls found that the life time 
risk of developing interstitial lung disease (ILD) was 7.7% for RA patients compared to 0.9% 
for non-RA controls and the risk of death for RA patients with ILD was 3 times higher than in 
RA patients without ILD [97]. In a cohort study analyzing the lungs using high resolution 
computed tomography (HRCT) found bronchiectasis in 35%, bronchial wall thickening in 
50%, ground-glass opacification in 18%, and reticular changes in 12% of the early RA patients 
[98]. It was also found that concentration of ACPA correlated with lung function parameter 
such as DLCO (impaired gas transfer) and bronchial wall thickening observed by HRCT.  In a 
study comparing HRCT lung changes between early and longstanding RA patients, the most 
frequent HRCT abnormality was the bronchial dilation (which is a hallmark of bronchiectasis) 
found in 33.8 % and 49.2 % of early and long-standing RA patients respectively. There was a 
significant difference in bronchial wall thickening (6.2 % in early RA vs 18 % in longstanding 
RA) and parenchymal micronodules (7.7 % vs 21.3 %). However no significant difference was 
observed in radiological lung abnormalities corresponding to interstitial pulmonary disease 
suggesting that the changes could be independent of disease duration [99]. In a study designed 
to identify the risk factors for ILD and airway disease (AD) in RA, found high titers of RF and 
anti-CCP, age (≥65), HLA DRB1*1502, sex and smoking as significant risk factors for ILD 
whereas high titers of RF and anti-CCP were a risk factor for developing AD [100]. There was 
a negative association between HLA DRB1*1502 allele and AD. Another finding of prominent 
interest is the analysis of ACPA fine specificity and its association with ILD, found that the 
RA patients with ILD had significant higher number of ACPA fine specificities compared to 
non-ILD [101]. Other autoantibodies such as antibodies against PAD3/4 which enhance 
citrullination have also been implicated in RA-associated ILD. Interestingly, RA patients 
having anti-PAD3/4 antibodies have a higher frequency of ILD (68%) compared to non-ILD 
RA (29%) [102]. These studies highlight the importance of lung as a secondary organ affected 
by the disease in RA and this could involve an interplay between environmental factors, 
genetics and autoantibodies.  
Aside from the macroscopic changes seen by HRCT, lungs are a site of inflammation 
and microscopic changes in RA. Analysis of bronchoalveolar lavage (BAL) cells and bronchial 
biopsies have shown the presence of citrullinated proteins [40, 44]. Analysis of bronchial 
biopsies from the lungs of early RA patients have shown a presence of increased lymphocyte 
infiltrates, inducible bronchus-associated lymphoid tissue (iBALT) structures, increase in 
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activation markers like CD3, HLA-DR and HLA-DQ compared to healthy controls [103].  
ACPAs have been detected in the BAL and sputum of early RA and were found to be enriched 
in the lungs compared to circulation [44, 104]. Analysis of lungs from RA patients with lung 
disease indicates the presence of iBALT structures and presence of  B cells capable of 
producing ACPAs [105] suggesting that lungs could be an organ for maturation and production 
of pathological autoantibodies in RA. 
 
1.9 Microbiome in RA 
Microbiome refers to the collection of microorganisms that are present in an 
environmental niche. In the human body, it has been proposed that there are approximately 10 
times more bacteria than the number of human cells and 100 times more bacterial genomic 
content than the human genome [106]. However, recent revised estimates suggest that 
approximately equal number of bacteria and human cells to be preset in the body [107].  
 
1.9.1 Methods to study microbiome  
Historically, the study of microbiome has been performed using labor-intensive culture 
based techniques, where only relatively small proportion of the bacteria could be studied. With 
the advent of sequence based technologies, it has been show that 80% of the bacteria present 
in our body have never been cultured before, because the laboratory conditions and nutrients 
do not favor the growth of all the organisms (especially anaerobes) [108]. The sequencing can 
be performed by two different methods. The first method is to use 16S rRNA sequencing that 
provides information on the identity of the bacterial communities present in an environmental 
niche and enables us to understand the complexity of the bacterial communities. This is based 
upon the sequencing of the 16S ribosomal RNA (16S rRNA) of the bacteria which is highly 
conserved and serves as the signature of a bacterial species. The 16S rRNA contains 
hypervariable regions that provide specific signatures, which enable the identification of 
bacteria present in a sample. The second approach is the whole genome shotgun sequencing, 
which allows us to study the various pathways the bacterial communities might be involved in 
and what they perform in the environment [109]. Using these approaches several sites in the 
human body including the airways, oral cavity, skin, gastrointestinal tract (gut) and urogenital 
tract have been studied [110]. 
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1.9.2 The Gut Microbiome  
The gut microbiome is the most commonly studied and its role in health and disease has 
been understood using human samples and animal models. The homeostasis (and protection) 
between the gut microbiome and immune system is maintained by a physical barrier provided 
by the tight epithelial cells and mucosal layer, biochemical products such as enzymes and 
antimicrobial proteins and immunological factors such as IgA and epithelia-associated immune 
cells [111]. The gut microbiota provides the host with a wide range of nutrients that the host 
produce in low amounts or is incapable of producing. The microbial flora produces short chain 
fatty acids (SCFAs) that are absorbed and used by the cells in various cellular processes. Lactic 
acid bacteria can support  the production of vitamin B12 and Bifidobacterium facilitate the 
folate production [106]. 
The gut is mostly dominated by bacteria from two phyla namely Firmicutes and 
Bacteroidetes [108]. Though the gut is continuous organ system, studies using mice have 
identified that the microbiome composition varies along the gastrointestinal tract with the 
gastric, duodenal, and large intestine having higher phylogenetic diversity than the jejunum 
and ileum [112]. Also, the communities found in the small intestine and stomach were different 
from those seen in the large intestine and fecal samples suggesting the existence of location-
based microbial ecosystem in the gut. Factors affecting the gut microbiome include diet, 
smoking, antibiotic- use, drugs, probiotics, prebiotics and enteric infections [113]. Age and sex 
are also factors that determine the microbiome composition. The change in bacterial 
community causing an imbalance is termed as dysbiosis and this has been studied in Obesity 
[114], Ankylosing Spondylitis [115], Inflammatory bowel disease [116], Type 1 diabetes [117] 
and Type 2 diabetes [118]. 
Gut dysbiosis in RA  has been previously studied from fecal samples using culture-based 
techniques demonstrating that the presence of Clostridium perfringens was higher in RA 
compared to healthy controls [119]. Another study using computerized gas-liquid 
chromatography (GLC) to investigate bacterial cellular fatty acids (CFAs) in the fecal samples 
found differences between RA and healthy controls suggesting dysbiosis [120]. Furthermore, 
a study comparing the fecal microbiome from healthy individuals, psoriatic arthritis (PsA), new 
onset RA and RA patients on treatment, found that the relative abundance of Prevotella 
increased and Bacteroides decreased in new onset RA as compared to healthy, PsA and treated 
RA [121]. The authors were able to identify Prevotella copri as a strain that was significantly 
abundant in new onset RA. Comparison between treated RA and early RA showed that, 
treatment was effective in bringing the balance between Prevotella and Bacteroides similar to 
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that seen in healthy individuals which the authors speculate could be due to treatment-
dependent decrease of inflammation. Another large study using fecal samples from a large 
cohort of RA and healthy individuals obtained similar results showing dysbiosis in the gut of 
RA compared to healthy, with enrichment of gram positive bacteria in the RA gut. Bacteria 
such as Haemophilus were over-represented in the healthy individuals whereas Lactobacillus 
salivarius was enriched in RA. In this study, the authors were able to compare the fecal samples 
from the same patient before and after treatment and found that treatment was able to restore 
the microbial balance [122]. 
Some of our understanding on the role of microbiome in RA comes from studies using 
animal models. In an adjuvant-induced (Mycobacterium bovis - BCG) arthritis model germ 
free rats developed more severe arthritis compared to specific pathogen fee rats which was 
enhanced by colonization with Bifidobacterium, Propionibacterium acnes, Lactobacillus 
casei, L. fermentum, L. murini, and L. acidophilus [123]. However, in a K/BxN mice model, 
germ free conditions attenuated the arthritis, and was enhanced by the colonization with 
segmented filamentous bacteria through a Th17 response [124]. Similarly, in an IL-1 receptor 
antagonist knockout (IL1rn–/–) mice model, germ free conditions did not favor the development 
of arthritis while colonization with Lactobacillus bifidus lead to the development of arthritis by 
a Th17 and TLR4 dependent mechanism [125]. These studies suggest that altering the 
microbial flora may trigger or exacerbate the diseases in RA. 
 
1.9.3 The Oral Microbiome 
The oral cavity is the entry portal of the gastrointestinal tract and is colonized by different 
microbial species. Although the oral microbiome is studied as a whole, many different habitats 
exist in the oral cavity and bacterial diversity different among these sites. The most prevelant 
phyla in the oral cavity are Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, 
Fusobacteria, and abundant species being Streptococcus [126]. Bacteria present in the oral 
cavity such as Porphyromonas gingivalis, a periodontopathic bacterium found in the gums is 
implicated in RA. This is because periodontitis is associated with RA and P.gingivalis is the 
only know bacterial to have its own PAD enzyme that can generate citrullinated proteins [127]. 
In a recent study using gingival cervical fluid (GCF) from individuals with and without 
periodontitis found that enrichment of Aggregatibacter actinomycetemcomitans in 
periodontitis patients compared to controls [128]. A. actinomycetemcomitans induces 
hypercitrullination via Leukotoxin A which forms pores creating an influx of extracellular 
calcium favoring the activity of PAD enzymes. Analysis of saliva and dental plaques from RA 
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patients and healthy individuals showed that bacteria such as Lactobacillus salivarius, 
Atopobium spp. and Cryptobacterium curtum were over-represented in the RA group. 
Interestingly P.gingivalis was over-represented in the healthy individuals in both the saliva and 
dental plaques, in this study [122].  
 
1.9.4 The Lung Microbiome 
Similar to the gut mucosa the airways are also colonized by bacteria, but unlike the gut 
the airways have a low bacterial burden. The upper respiratory tract has a higher bacterial 
burden of about 100 to 10,000 times more bacteria than the lower respiratory tract [129], which 
makes it challenging to study lung microbiome due to high noise and low signal. Differences 
in microbiome can be observed in different regions of the upper airways with studies displaying 
that phyla present in the nasopharynx (nasal cavity) were Firmicutes (73%), Proteobacteria 
(12.6%), Bacteroidetes (7%), and Actinobacteria (5.6%); in the oropharynx (oral cavity) the 
principal phyla were Bacteroidetes (36.4%), Firmicutes (27.7%), Proteobacteria (12.6%), and 
Fusobacteria (12.3%) [130]. In a study comparing microbiome of nasal cavity, oral cavity, 
lungs and stomach (gastric juice) of healthy individuals found that the oral microbiota but not 
nasal microbiota, overlapped with that of the lungs though with a very low relative abundance 
[131]. One of the ways of delivery of microbiota to the lower airways could be due to 
microaspirations which is common in both health and disease states [132]. 
In a study comparing the BAL of healthy individuals versus COPD patients, it has been 
demonstrated that the diseased lungs have lower diversity and abundance of bacteria [133]. 
The study also highlights some of the core pulmonary bacterial microbiome present in lower 
airways such as Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Haemophilus, 
Veillonella, and Porphyromonas. In an investigation comparing oral wash and BAL from 
healthy smokers and non-smokers showed that though the overall bacterial community in the 
lung resembles that of the oral cavity, there were distinct bacterial species that were 
overrepresented in the lung [134]. Though there was no significant decrease in diversity of 
bacterial communities, a decrease in relative abundance of Bacteroidetes and Proteobacteria in 
the BAL of smokers compared to non-smokers was observed. Differences in lung microbiome 
can be observed during disease conditions such as Chronic Obstructive Pulmonary Disease 
(COPD) [135] and Asthma [136] with some taxa correlating with the disease parameters. Not 
much is understood about the microbiome perturbation caused by smoking and inflammation 
in the lungs of RA and studies looking into this aspect with feasible designs are important in 
understand how they play a role in the etiology in RA. 
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1.10 Model for etiology and pathogenesis of RA 
The disease manifestation in RA is different in ACPA positive compared to ACPA 
negative individuals, with the known environmental (such as smoking) and genetic factors 
(HLA-DR SE) associated to the ACPA positive and not ACPA negative disease [11]. There is 
a complex interplay between genetic and environmental factors that leads to immunity, which 
breaches a ‘tolerance threshold’ leading to the onset of the disease. Here I have summarized a 
model for the etiology and pathogenesis of ACPA positive RA based on existing knowledge.  
Epidemiological investigation in a large population-based twin cohort suggests that the 
environmental factors (such as smoking and silica) play an important role in the development 
of ACPAs whereas the genetic factors (HLA-DR SE) might play a larger role in development 
of ACPA positive RA, called step wise development of RA model [137]. The presence of 
ACPA (detected by CCP2) [62, 76], anti-CCP (IgA, IgG, IgM) [138], RF (IgA, IgG and IgM) 
[139] in circulation long before the onset of the disease might suggest that immunity in RA 
arises in organs other than the joints. Possible organs could be the mucosal surfaces such as the 
gut, gums and/or lungs. Epidemiological data suggests a strong association between smoking 
and the development of ACPA and ACPA positive RA, makes the lungs one of the strong 
candidates for the site for initiation of autoimmunity in RA. 
The lung faces a lot of environmental insults and offers wide range of physical, innate 
and adaptive immune protection. The epithelial cell surface of the lungs are directly exposed 
to environmental and external pollutants such as dust, silica and cigarette smoke which affects 
the physical barrier provided by the epithelial layer by increasing its permeability [140]. 
Investigation of the bronchial mucosal biopsies and bronchoalveolar lavage (BAL) cells from 
healthy smokers and non-smokers, showed that smoking increases citrullination and expression 
of PAD2 enzymes [40].  Cigarette smoke affects the alveolar macrophages to become more 
apoptotic [141] and activates them to produce pro-inflammatory mediators [142]. In vitro 
stimulation of bronchial epithelial cells with cigarette smoke extract increased the production 
of chemoattractant IL-8 that attracts neutrophils. This correlated with in vivo data from human 
BAL samples where an elevation in IL-8 among smokers, correlated with the number of 
neutrophils present in the BAL [143]. Neutrophils produce NETs which are a source of 
different citrullinated autoantigens in RA [144]. A recent study using transgenic mice carrying 
RA-susceptible *0401- genes exposed to cigarette smoke, displayed high levels of PAD 
expression and antibodies against native and citrullinated vimentin compared to RA resistant 
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*0402 animal controls [145]. These studies show that environmental stimuli in the lungs lead 
to the generation of modified autoantigens (figure 3). 
 
Figure 3: Early immune events in the lungs of RA. Environmental triggers (such as smoke, 
silica, dust and agents such as microorganisms) can lead to an increase in PAD enzymes and 
citrullination. The generation of the autoantigens leads to activation of antigen presenting cells 
(APCs with subsequent activation of T cells (T) and B cells (B) and local production of ACPAs 
(adapted from [148]). 
 
Then generation of autoantigens could lead to local production of autoantibodies in the 
lungs. Autoantibodies (ACPA and RF) were found in the sputum of individuals at risk of 
developing RA [104]. Studies in BAL from early untreated RA have shown the presence of 
ACPA (IgA and IgG) in the lungs [44]. The ACPA that are generated in individuals that are at 
risk to develop RA might then undergo affinity maturation. Analysis of blood donor samples 
predating the disease onset found expansion of ACPA fine specificities close to onset of RA 
and the epitope expansion was closely correlated with the appearance of preclinical 
inflammation [101]. Another feature before the onset of disease is the arthralgia that is observed 
in many ACPA positive subjects [146]. Studies in mice have shown that ACPA injected 
intravenously cause pain-like behavior in mice without arthritis [92]. Using micro computed 
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tomography (CT) to study the joints of these mice it was observed that ACPAs significantly 
reduced the trabecular bone mineral density and bone volume fraction compared to control 
antibodies [91]. This observation falls in line with studies on ACPA positive and ACPA 
negative healthy individuals undergoing micro-CT, finding a significant decrease in bone 
mineral density in ACPA positive healthy individuals [147]. This suggest that bone loss in RA 
starts prior to the onset of the clinical disease symptoms (longitudinal events summarized in 
figure 4). 
The breach of tolerance first leading to systemic autoimmunity and later to disease in RA 
might require an  additional hit [148]. The exact nature of what causes the trigger to the disease 
is yet to be deciphered. Another aspect that requires further understanding is the propagation 
of immunity arising at the mucosal sites and transitioning to the joints. We aimed to address 
that by searching for shared immunological targets in the lungs and joints, which will be 
discussed in detail in this thesis. 
 
Figure 4: Model for longitudinal development of RA. The figure summarized a model for the 
development of ACPA positive RA. 
 
Other models for the etiology and pathogenesis of the disease might exist that could be 
independent of the HLA-DR SE, PTPN22, smoking or lungs. But the fascinating aspect of the 
disease is that, no matter when the immunity starts, it finally ends up targeting the joints which 
might suggest that there might be a common factor that could link all this different initiating 
events in RA. 
 
RA
Time
At	Risk	RA At	High	Risk	RA
HLA-DR Smoking
Dust, Silica
Genes Environment
Healthy Systemic Autoimmunity Arthralgia Arthritis
Clinical	
Phenotype
Mucosal	Activation
ACPA
Inflammation	and	immune	activation
Autoantibody	Expansion
Pain	and	bone	loss Synovial	Inflammation
Genetic	Susceptibility
Synovial	Challenge
Chronic	joint	inflammation
  19 
2 AIMS 
The general aim is to characterize the anti citrulline immune responses (both antibodies 
and antibody-producing cells) and its impact on inflammation, within and outside the joint of 
RA. 
Specific aims are: 
• To investigate ACPA-response in relation to lung abonormalities in early-untreated RA 
(paper I). 
• To investigate the lung microbiome in in early-untreated RA (paper II). 
• To investigate the immunoligcal link between the lungs and joints in RA (Paper III). 
• To identify new articular and extra-articular ACPA targets (paper III and IV). 
• To characterize immunity against new discovered targets (paper III and IV). 
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3 MATERIALS AND METHODS 
 
This section summarizes the biological materials obtained from various cohorts and the 
methods used for the different analysis. More detailed description can be found in each paper.  
 
3.1 Subjects 
Different biological material was obtained from patients and controls. The ethical review 
board of the Karolinska University Hospital approved all the studies included in this thesis and 
all patients and controls gave informed consent. 
 
3.1.1 LURA Cohort (Paper I, II, III) 
The lung investigation in newly diagnosed RA (LURA) cohort is a unique cohort of new-
diagnosed RA patients (n=134) according to the ACR 1987 classification criteria [6] with 
patient reported symptom of less than 1 year, naïve to treatment with oral glucocorticoids and 
disease modifying anti-rheumatic drugs (DMARDs). Pregnancy, alcohol and/or drug abuse 
were exclusion criteria. Serum was obtained during the time of visit to the clinic and clinical 
parameters such as DAS28 were measured. HRCT and spirometry was performed on 106 
(consecutive) patients. Some of the patients (n=20) underwent bronchoscopy during which 
bronchial biopsy and bronchoalveolar lavage (BAL) was obtained. The patient demographics 
of the different sample groups is summarized in table 1. 
 
Table 1: LURA Cohort. Demographics of patients from whom serum, bronchoalveolar lavage 
and bronchial biopsies were obtained.  
 
  HRCT Bronchoscopy 
 Serum Serum BAL 
Bronchial 
 Biopsies 
Number 134 106 20 6 
Age (years), Median (Range) 57 (20-84) 61 (23-85) 59 (28-76) 59.5 (23-68) 
Female, n (%) 91 (67.9 %) 73 (68.9 %) 8 (40 %) 4 (66.7%) 
ACPA positive, n (%) 88 (65.7 %) 71 (67.0 %) 16 (80.0 %) 4 (66.7%) 
Smoking     
Non-smokers, n (%) 38 (28.4 %) 29 (27.4 %) 4 (20.0 %) 3 (50.0 %) 
Ex-smokers, n (%) 58 (43.3 %) 46 (43.4 %) 7 (35.0 %) 1 (16.7 %) 
Current smokers, n (%) 38 (28.4 %) 31 (29.2 %) 9 (45.0 %) 2 (33.3 %) 
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3.1.2 RA Cohort (Paper II, IV) 
Serum was obtained from an early RA cohort called EIRA which has been described 
previously [11] and was used in the analysis for paper III. Serum was obtained from a cohort 
of established RA patients undergoing joint arthrocentesis and was used for analysis in paper 
IV. Synovial biopsies were obtained from patients with long standing RA undergoing 
orthopedic surgery. The patient demographics of the different sample groups is summarized in 
table 2. 
Table 2: RA Cohort. Demographics of patients from whom serum and synovial biopsies were 
obtained. NA denotes data not available. 
 
 
3.1.3 Disease Controls (Paper II, III, IV) 
Serum was obtained from patients with Psoriatic arthritis (PsA) or Ankylosing 
spondylitis (AS) to be used as disease controls in paper III and IV.  
Table 3: Disease Controls. Demographics of the serum and BAL samples obtained from 
patients with PsA, AS and Sarcoidosis to be used as disease controls. NA denotes data not 
available. 
 
  EIRA Established RA   
  Serum Serum Synovial Biopsy 
Number 259 347 7 
Age (years), Median (Range) 56 (20-70) 58 (21-94) 40 (30-63) 
Female, n (%) 187 (72.2 %) 277 (79.8 %) 5 (71.4 %) 
ACPA positive, n (%) 135 (52.1 %) 250 (72.0 %) 5 (71.4 %) 
Smoking    
Non-smokers, n (%) 76 (31.0 %) NA NA 
Ex-smokers, n (%) 70 (28.6 %) NA NA 
Current smokers, n (%) 99 (40.4 %) NA NA 
 
  PsA / AS Sarcoidosis 
  Serum BAL 
Number 236 10 
Age (years), Median (Range) 47 (18-85) 40 (30-63) 
Female, n (%) 115 (48.7 %) 3 (30.0 %) 
ACPA positive, n (%) 10 (4.2 %) 0 (0 %) 
Smoking   
Non-smokers, n (%) NA 4 (40 %) 
Ex-smokers, n (%) NA 4 (40 %) 
Current smokers, n (%) NA 2 (20 %) 
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BAL and serum was obtained from patients with sarcoidosis to be used as disease 
controls in our study of the lung microbiome. Detailed characteristics of the disease status have 
been described in paper II. The patient demographics of the different sample groups is 
summarized in table 3. 
 
3.1.4 Healthy Controls (Paper I, II, III, IV) 
Serum and BAL was obtained from healthy volunteers. For paper II, the study of the lung 
microbiome, BAL was obtained from healthy individuals with normal x-ray and no clinically 
relevant lung disease. The demographics of the different sample groups is summarized in table 
4. 
Table 4: Healthy Controls. Demographics of the serum and BAL samples obtained from 
healthy individuals. NA denotes data not available. 
 
 
3.2 High Resolution Computed Tomography and Spirometry (Paper I) 
HRCT was performed on RA patients (n=106) of the LURA cohort. The HRCT images 
were blindly assessed by an experienced radiologist and a pulmonologist. The HRCT 
abnormalities were categorized as the following: 
• Airway abnormalities - Bronchiectasis, air trapping and air wall thickening  
• Parenchymal abnormalities - Nodules larger than 3mm, ground glass opacities, 
opacities, fibrosis and emphysema 
Spirometry was performed to assess the working capacity of the lungs. The forced 
expiratory volume in 1 second (FEV1), vital capacity (VC), forced vital capacity (FVC) and 
diffusing capacity for carbon monoxide (DLco) were measured and used for analysis. Detailed 
description of the method can be found in paper I. 
  Serum BAL 
Number 152 28 
Age (years), Median (Range) 57 (23-71) 28 (19-50) 
Female, n (%) 107 (70.4 %) 14 (50%) 
ACPA positive, n (%) 5 (3.3 %) 1 (3.6 %) 
Smoking   
Non-smokers, n (%) NA 14 (50 %) 
Ex-smokers, n (%) NA 0 
Current smokers, n (%) NA 14 (50 %) 
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3.3 HLA-DR and PTPN22 Genotyping (Paper I, III, IV) 
The RA patients were genotyped for the HLA-DRB1 allele as described previously [149] 
and HLA-DRB1*0101, *0102, *0401, *0404, *0405 or *1001 alleles were classified as HLA-
shared epitope (HLA-SE) alleles [9]. In total 322 of the 347 established RA patients (in paper 
IV) were genotyped to identify the PTPN22 R620W risk allele carriers as described previously 
[150]. 
 
3.4 Microbiome Analysis (Paper II) 
Microbiome analysis was performed on the BAL to identify the dysbiosis of the lungs. 
This was performed using the 16S rRNA V4 gene sequencing which acts as a unique signature 
to identify different taxa present in any given sample.  
 
3.4.1 DNA Extraction and Sequencing 
Bacterial DNA was extracted from the BAL samples using the Qiagen DNA extraction 
kit. High throughput sequencing of the 16s rRNA V4 region was performed using the MiSeq 
Illumina sequencer.  
 
3.4.2 Microbiome sequence Analysis 
The 16s rRNA sequences obtained were analyzed using the Quantitative Insights into 
Microbial Ecology (QIIME) pipeline for analysis of community sequence data. The reads were 
de-multiplexed and quality filtered with default parameters using prinseq. Sequences were then 
clustered into operational taxonomic units (OTUs) using a 97% similarity threshold with 
USEARCH and the Greengenes 16S reference dataset and taxonomy [151]. To avoid bias due 
to the different number of sequences per sample, 3687 sequences (minimum number of 
sequences found in a given sample) were used per sample in order to define OTUs and 
taxonomic composition and ade4 package in R was used to construct Principal Coordinate 
Analysis (PCoA) based on unweighted UniFrac distances. 
 
3.5 Mass Spectrometry (Paper III) 
Mass spectrometry was used to identify citrullinated peptides in the synovial and 
bronchial biopsies. Briefly, the samples were homogenized by shaking with ceramic beads 
followed by sonication. After reduction and alkylation, the proteins were digested with Lys-C. 
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The samples were then passed through Liquid chromatography (LC) and MS/MS analysis was 
performed. The peptides were identified using the Mascot search engine using the human IPI 
database. All citrullinated peptides identified had a Mascot score of at least 20. Detailed 
description of the methodology can be found in paper III. 
 
3.6 Detection and Measurement of Autoantibodies 
Enzyme-Linked Immunosorbent Assay (ELISA) based methods allow for quantitative 
and qualitative measurement of autoantibodies in the serum. 
The ACPAs were detected and measured using commercial CCP2 ELISA kit 
(Eurodiagnostica, Malmö, Sweden) following the protocol provided by the manufacturer. The 
cut-off for positivity was 25 Au/ml as recommended.  
Fluoroenzyme immunoassay EliA (Phadia, Uppsala, Sweden) was used to measure IgA 
and IgA anti-CCP2 antibodies and IgM and IgA RF. The assay was performed according to 
the instructions provided by the manufacturer and positivity for the assay was determined by 
the cut-off provided by the manufacturer.  
 
3.6.1 Multiplex peptide chip-based assay (Paper I, II) 
Detection of ACPA fine specificities against different citrullinated peptide antigens were 
performed using a custom peptide array method based on the Immuno Solid-phase Allergen 
Chip (ISAC) (Phadia, Uppsala, Sweden) platform that is used to screen for immunity against 
allergens.  
Peptides both in the citrullinated and native form are printed in spots onto a glass slide 
(table 5). Serum samples, diluted 1:40 in dilution buffer (Phadia, Uppsala, Sweden), were 
incubated on the slides and bound autoantibodies were detected using a Cy3 conjugated goat 
anti-human IgG (Jackson ImmunoResearch Laboratories, Newmarket, UK). The fluorescence-
intensity was measured and converted to arbitrary units (Au/ml) based on an internal calibrator 
present in each chip. The cut-off values were determined as the 98th percentile of the healthy 
control reactivity. 
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Table 5: Peptides in ISAC peptide array.  The sequence and citrulline positions of the different 
peptides used in the ISAC peptide array. * denotes Cyclic Peptides. 
 
 
3.6.2 In-house Enzyme-Linked Immunosorbent Assay (Paper III, IV) 
Antibodies to various other citrullinated antigens were measured using in-house ELISA. 
The different antigens used is summarized in table 6.  
 
Table 6: Peptides used for the in-house ELISA. Fib are peptides from protein fibrinogen α-
chain and Vim is peptide from vimentin protein. O represents biotin, Z represents 6-
aminohexanoic acid 
 
 
The biotinylated peptides both in the citrullinated and native form, were incubated in a 
streptavidin coated high binding capacity plates (Thermo Scientific, Gothenburg, Sweden). 
Serum was diluted 1:100 for detection of citrulline reactive autoantibodies. The bound 
antibodies were detected with horseradish peroxidase-conjugated goat anti-human IgG F (ab)2 
(Jackson ImmunoResearch, Newmarket, UK). Detection was performed using the 
chromogenic substrate, 3, 3, 5, 5-tetramethyl-benzidine (Sigma-Aldrich, Stockholm, Sweden), 
 
Name of Peptide Protein Amino acids Amino acid sequence 
CEP-1 α-Enolase 5-21 CKIHA(cit)EIFDS(cit)GNPTVEC* 
CCP-1 Filaggrin 307-324 SHQEST(cit)GRSRGRSGRSGS* 
Vim 2-17 Vimentin 2-17 ST(cit)SVSSSSY(cit)(cit)MFGG 
Vim 60-75 Vimentin 60-75 VYAT(cit)SSAV(cit)L(cit)SSVP 
Fibα 36-50 Fibrinogen α-chain 36-50 GP(cit)VVE(cit)HQSACKDS 
Fibα 563-583 Fibrinogen α-chain 563-583 HHPGIAEFPS(cit)GKSSSYSKQF 
Fibα 580-600 Fibrinogen α-chain 580-600 SKQFTSSTSYN(cit)GDSTFESKS 
Fibα 621-635 Fibrinogen α-chain 621-635 (cit)GHAKS(cit)PV(cit)GIHTS 
Fibβ 36-52 Fibrinogen β-chain 36-52 NEEGFFSA(cit)GHRPLDKK 
Fibβ 60-74 Fibrinogen β-chain 60-74 (cit)PAPPPISGGGY(cit)A(cit) 
Name of Peptide Amino Acid Sequence of the Peptide 
Fib α 35 29-41 AEGGGV(Cit)GPRVVE-ZO 
Fib α 216,218 201-225 KDLLPS(Cit)D(Cit)QHLPLIK-ZO 
Fib α 263,271 256-278 QMRMELE(Cit)PGGNEIT(Cit)GGSTSYG-ZO 
Fib α 425,426 419-432 NVSPGT(Cit)(Cit)EYHTEK-ZO 
Vim 435-455 435-455 O-DTHSK(Cit)TLLIKTVET(Cit)DGQVI 
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and absorbance was measured at 450 nm with reference at 650 nm. A standard was included 
in each plate to convert absorbance into arbitrary units (AUs). The cut-off values were 
determined as the 98th percentile of the healthy control reactivity. 
 
3.7 Tetramer Production and Flow cytometry (Paper IV) 
Antigen-specific B cells were detected using peptide tetramers. It consists of an R-
Phycoerythrin (PE) labelled streptavidin (SA) core connected to four identical biotinylated 
peptides. The tetramers were assembled and used for B cell detection as described previously 
[152]. 
 
Figure 5: B cell antigen tetramers. Representation of the B cell tetramer, where SA is the 
streptavidin core, PE is the R-Phycoerythrin fluorochrome, AF647 is the Alexa Fluor 647 
flurochrome and cit and arg are the biotinylated citrulline and arginine peptides. The native, 
arg fibrinogen tetramer servers as the decoy. 
 
The biotinylated citrullinated fibrinogen (cit-fib) peptides used in ELISA were incubated 
with SA-PE (Prozyme, Hayward, CA, USA) at a molar ratio of 10:1 and the tetramer fraction 
was purified using a 100-kD molecular weight cut-off Amicon Ultra filter (Millipore, 
Stockholm, Sweden). After measuring the concentration of PE by Nanodrop (Thermo Fischer, 
Gothenburg, Sweden), the molarity of the tetramer was calculated with the supplier-determined 
ratio of SA to PE. The decoy tetramer was prepared using the same protocol as described above, 
by incubating the biotinylated native, non-citrullinated fibrinogen (fib) peptides with SA-PE 
pre-conjugated to Alexa Flour 647 (Molecular Probes Invitrogen). The four α-chain derived 
Fib peptides were assembled as tetramers separately and then pooled at the time of sample 
staining. The decoy tetramers were assembled and used in the same manner with the 
corresponding native fib peptides. 
To detect the tetramer positive B cells, PBMCs were isolated from blood of RA patients 
by Ficoll-paque (GE Healthcare, Uppsala, Sweden), and stained with the decoy and cit-fib 
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tetramers in buffer containing Fc blocking solution (FcR Blocker Miltenyi Biotec, Lund, 
Sweden), followed by incubation with anti-PE magnetic beads (Miltenyi Biotec) then passed 
over a magnetized LS column (Miltenyi Biotec) to enrich for tetramer-binding cells. Both the 
bound and flow-through fractions were stained with APC-H7 labelled anti-CD3, APC-H7 
labelled anti-CD14, APC-H7 labelled anti-CD16, BV421 labelled anti-CD19, V500-C labelled 
anti-CD20, PE-Cy7 labelled anti-CD27 and FITC labelled anti-IgD (all antibodies from BD 
Biosciences, Stockholm, Sweden). The samples were analyzed by flow cytometry using a 4 
laser (405nm, 488nm, 561nm and 640nm) LSR Fortessa (BD Biosciences, Stockholm, 
Sweden) and analyzed with FlowJo software (Tree Star). Fluorescent AccuCheck counting 
beads (Invitrogen, CA, USA) were used to calculate total numbers of live lymphocytes in the 
column-bound and flow-through suspensions. The gating strategy for tetramer staining was 
based on a FSC/SSC lymphocyte gate and removal of doublets followed by elimination of 
CD3, CD14 and CD16 positive cells before assessment of the B cell subset. 
 
3.8 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism (version 6.0) and SPSS 
software. Comparison between two groups of continuous variables was performed using t-test 
(parametric) and Mann Whitney U test (non-parametric) and between multiple groups by 
analysis of variance. Chi-square test (or Fischer’s exact) was performed to analyze the 
association between categorical variables (example: antibody reactivity vs genetic risk factors). 
Binomial logistic regression analysis was performed to assess the relationship between 
categorical variables and a set of predicating variables (example: HRCT lung abnormalities vs 
age, sex, presence of ACAP fine specificities). The p values less than 0.05 were considered 
significant. 
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4 RESULTS AND DISCUSSION 
4.1 Signs of Immune activation and inflammation are present in the lungs of early 
untreated RA 
As discussed earlier, the association between smoking and ACPA, the presence of ACPA 
in circulation long before the onset of RA and the expansion of ACPA repertoire occurring 
close to the onset of joint inflammation [80] suggest that immunity in RA might be triggered 
in the mucosal surfaces such as the lungs. Investigation of the lungs can be performed by 
imagistic methods (HRCT), microscopic analysis of lung/bronchial biopsies and biochemical 
methods of BAL or induced sputum using ELISAs and flow cytometry. Here we employed 
some of these methods to study the lungs in early untreated RA patients. 
 
 
Figure 6: Signs of inflammation and ACPAs in the lungs of early untreated RA. The left 
panel shows the representative images of the bronchial biopsy histology from ACPA negative 
and positive RA patients. The first row shows the presence of infiltrates using a hematoxylin 
and eosin staining. The second row is the CD3 staining for T cells, the third row for HLA-DR 
and the last row is the identification of citrullination using ACPA isolated from serum of RA 
patients (affinity purification using CCP2 column). The panel on the right shows the CCP2 IgG 
and IgA measurement normalized to total IgG and IgA in paired serum and BAL samples from 
early RA (adapted from [44, 103]). 
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Previous understanding of the RA lung pathology/histology originates from studying 
biopsies from patients with long standing RA [105] and ACPA positive individuals with lung 
disease [153]. Both these studies have showed the presence of ectopic lymphoid structures in 
some of the ACPA positive individuals. Using bronchial biopsies form early untreated RA 
patients we found that 50% (9/18) of ACPA positive RA has presence of lymphocyte infiltrates 
compared to 17% (1/6) in ACPA negative and 13% (2/15) in healthy individuals. CD3+ T cells 
were more frequent in the ACPA positive RA and CD19+ B cells were present (4/18) only in 
the ACPA positive bronchial biopsies. Investigation of immune activation markers like HLA-
DQ and HLA-DR was upregulated in the lungs of ACPA positive compared to ACPA negative 
RA. These results are indicative of subtle inflammatory events in the lungs of early RA and 
especially in the lungs of ACPA positive RA patients (figure 6). 
Previous studies by our group have shown the presence of increased citrullination in the 
BAL cells of smokers compared to non-smokers [40].  To identify citrullination in the lung of 
early RA, we used ACPAs isolated from serum of RA patients by affinity purification using 
CCP2 columns [154]. Using these antibodies, we found increased citrullination in the lungs of 
ACPA positive (median histological score 1, range 0-2) compared to ACPA negative (median 
histological score 0, range 0-1) RA patients. To further explore if the anti-citrulline immunity 
existed in the lungs, we analyzed the BAL of RA patients for the presence of ACPA. After 
normalizing for the total IgG and IgA content, we found an enrichment of ACPA (IgG and 
IgA) in the BAL compared to paired serum samples from patients. These results were similar 
to the observation of ACPA and RF in the sputum of individuals at risk of RA and early RA 
[104]. This higher ratio of ACPA in the mucosal compartment supports the notion of local 
production of antibodies in the lungs of RA patients. 
 
4.2 HRCT Parenchymal lung abnormalities are associated with increased in ACPA 
fine specificities in early untreated RA 
The presence of macroscopic abnormalities assessed by HRCT abnormalities are 
common among early RA patients compared to controls [44] and expansion of ACPA fine 
specificities is linked to RA-associated ILD [101]. We assessed the role of ACPA fine 
specificities and its influence on the HRCT lung abnormalities in a cohort of early untreated 
RA patients. 
Among the 106 RA patients included in the study, 58 (54.7%) had parenchymal 
abnormalities, 68 (64.2%) had airway abnormalities and a considerable proportion of patients, 
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41 (38.7%) had both parenchymal and airway abnormalities. Individuals with parenchymal and 
airway abnormalities were significantly older. Those having parenchymal abnormalities were 
mostly smokers (% of smokers among those without vs with parenchymal abnormalities, 
62.5% vs 81.0%) and had significantly higher pack years (Median 3.0 vs 17.3) of smoking. 
There was a significant association between the presence of ACPA (anti-CCP2) and HRCT 
parenchymal abnormalities, whereas no such association was observed for airway 
abnormalities. Those having airway or parenchymal abnormalities had significantly decreased 
FEV1 whereas the FVC was significantly decreased in those having airway abnormalities and 
FEV1/FVC was significantly decreased in those having parenchymal abnormalities (Table 2, 
Paper I). 
We performed a univariate logistic regression and found that: age greater than 65 years 
[OR (95%CI): 2.4(1.1-5.6) p value: 0.04], ever smoking [2.6(1.1-6.2), 0.04], pack years greater 
than 23 [6.3 (1.9-21.4), 0.003] and presence of anti CCP2 antibodies [2.9 (1.3-6.8), 0.01] were 
all significant associated with parenchymal abnormalities (Supplementary table 2, Paper I). 
After adjusting for age, sex and smoking, the HRCT parenchymal abnormalities were found to 
be associated with RF (both IgM and IgA) and CCP2 IgG, antibodies against any one cit 
vimentin peptide, especially cit vimentin 60-75, or antibodies against any one cit fibrinogen 
peptide, especially cit fibrinogen alpha 563-583 and cit fibrinogen beta 60-74. After stratifying 
based on smokers, RF IgA, CCP2 IgG, cit vimentin reactivity, cit fibrinogen reactivity still 
remained as good predictors of parenchymal abnormalities (Table 3, Paper I). The presence of 
high number of ACPA fine specificities (greater than 5) increased the risk for parenchymal 
abnormalities, especially among ever smokers, 7 times in case of more than 5 ACPA fine 
specificities and 4 times in case of less than 5 ACPA fine specificities. No such significant 
associations were observed for airway abnormalities (Figure 7). 
Lung changes using CT has been previously demonstrated in early RA [98, 99], early 
untreated RA [44], long standing RA [155] [99] and in ACPA positive subjects [156]. In this 
study, our data demonstrates an association of some ACPA fine specificities with parenchymal 
but not airway abnormalities in early untreated RA. Association between ACPA fine specificity 
and ILD has been demonstrated previously in a cohort of RA patients, under medication. The 
strength of the current studies lies in the fact that the patients in our cohort have a disease 
duration less than one year and have not been under DMARDs which might influence the lungs 
[157]. The association between parenchymal abnormalities might suggest a more intrinsic 
immune mechanism developing in the lungs during the early disease onset.  The understanding 
on what the ACPA fine specificity mean in causing these changes needs careful exploration 
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and interpretation. The unique RA cohort provides new insights of lungs and airway 
involvement in RA with more research needed to further explore the link between the influence 
of antibody-mediated lung-immunity and RA. 
 
Figure 7: Association between number of ACAP fine specificities and HRCT lung 
abnormalities. The forest plot represents the odds ratio (95%CI), between the number of ACPA 
fine specificities (0-reference, 1-5 and >5) and presence of Parenchymal or Airway 
abnormalities. The significant OR (p Value < 0.05) are represented by red circles (•). 
 
4.3 Distal airway dysbiosis is present in the early untreated RA 
The dysbiosis (microbial imbalance) at mucosal sites leading to the trigger and 
exacerbation of RA has been previously hypothesized and reviewed [109]. Prior knowledge of 
the role of microbiome in RA is based on animal [123, 124] and human studies [121, 122, 158] 
involving the gut microbiome. Studies have revealed that the gut microbiome in RA patients is 
perturbed compared to healthy controls and can be normalized after treatment [121, 122]. In 
study II we planned to explore whether there is a difference in the lung microbiome in RA 
compared to healthy or another disease condition. We used BAL fluid obtained by research 
bronchoscopy from individuals with RA, Sarcoidosis and healthy, to look into the lung 
microbiome. 
The 16srRNA V4 gene sequences was used to identify the different taxa present in the 
samples. We first analyzed the alpha diversity of the sample groups, which measures the 
richness (number) and evenness (distribution) of the taxa. Compared to the healthy controls, 
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the BAL microbiome alpha diversity was significantly reduced in the RA and sarcoidosis 
(figure 8). The Healthy BALs had significantly higher number of OTUs as compared to RA 
and sarcoidosis. Whereas no difference in alpha diversity was observed between RA and 
sarcoidosis as calculated by the number of OTUs, Simpson’s diversity index and Faith’s 
phylodiversity Index displayed in figure 8. 
 
 
Figure 8: Alpha diversity of lung microbiome. The figure represents the alpha diversity of the 
BAL microbiome calculated using (a) the number of OTUs (b) Simpson’s diversity index and 
(c) Faith’s phylodiversity index.  
 
We then analyzed the beta diversity, which measures the between-sample taxonomic 
diversity. Using PCoA to cluster the samples and ANOSIM test, the beta-diversity plot (figure 
9) demonstrated significant difference between healthy compared to RA and sarcoidosis (p 
value = 0.002 and 0.021) whereas no significant difference was observed between the RA- and 
sarcoidosis patients (p value = 0.265). The lower abundance of microbiome in RA compared 
to healthy is in line with previous study investigating the gut microbiome in RA [121]. 
Interestingly the microbiome abundance in RA was similar to that of sarcoidosis, which is an 
inflammatory disease of the lungs. These findings support the hypothesis that changes in the 
lung microbiome might contribute to the disease pathogenesis in the early stages of RA. 
In order to understand which bacterial taxa were different among healthy and the disease 
groups, we analyzed the relative abundance of the most abundant taxa. Families 
Actinomycetaceae, Spirochaetaceae, genus Burkholderia, Treponema were enriched in the 
healthy compared to RA. Very few taxonomic differences were observed between RA and 
sarcoidosis. For example, the relative abundance of the OTU aligned to the genus 
Pseudonocardia was higher in RA compared to healthy and sarcoidosis (figure 10). By further 
stratification of RA patients based on the presence of joint erosions, we found a higher relative 
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abundance (p value = 0.0093) of this taxa in patients having an erosive joint disease. 
Pseudonocardia is known to be an antifungal commensal microorganism [159] but its presence 
in relation with the fungal profile of the BAL was not explored in this study. 
 
Figure 9: Beta diversity of lung microbiome. The PCA plot represents the beta diversity 
between the healthy (Blue), RA (Red) and Sarcoidosis (Green). The RA are more clustered 
together with the sarcoidosis compared with the healthy individuals. 
 
We further investigated the association between the alterations in microbial composition 
in early RA with phenotypic characteristics at the time of sampling. We found a positive 
correlation between DAS28 and the genus Megasphaera and Renibacterium and OTUs 
belonging to Pseudonocardia, Streptococcus, and Xanthomonadaceae but was negatively 
correlated with genus unclassified Oxalobacteraceae. Serum and BAL anti-CCP2 positively 
correlated to genus unclassified Comamonadaceae. Presence of eosinophils in the BAL 
positively correlated with some OTUs belonging to the genus Pseudomonas. The exact nature 
of contributing of these taxa to the decrease or increase of various disease or immune related 
parameters requires additional studies with larger study cohorts.  
Through this study we were able to show that the lung microbiome in early untreated RA 
is different compared to healthy individuals but similar to lung inflammatory conditions such 
as sarcoidosis. We have previously demonstrated the presence of subtle lung inflammation and 
presence of antibodies in the lungs of RA [44, 160], if the dysbiosis is a consequence or an 
enhancer of these immune events in the lungs of RA requires further investigation. To our 
knowledge, this is the only study performed to investigate the distal airway microbiome in RA. 
One of the drawbacks of this study could be the small sample size. Inclusion of paired samples 
ANOSIM Test 
Healthy vs RA: p=0.002 
Healthy vs Sarcoid: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthy
 RA 
 Sarcoid 
PC1 (9%)
PC
1 
(7
%
)
Beta Diversity
  35 
from the gut might also add further insight into the relationship between the lung and gut 
microbiome in early RA. 
 
Figure 10: Pseudonocardia OUT (630556) in the lungs of RA. The bar graph (left) represents 
the difference in relative abundance of Pseudonocardia OUT (630556) in healthy compared to 
RA and Sarcoidosis and (right) the RA patients stratified based on the presence of joint 
erosions. 
 
4.4 Shared immunological targets are present in the lungs and joints of RA 
The role of mucosal sites, especially the lungs as an initiation site for RA has been 
described [161] but very little is known how the immunity can be transferred from the lungs to 
the joints, which is the central site of disease manifestation  in RA. One possibility is the 
presence of shared immunological targets in the lungs and joints, whereby the immunoreactions 
initiated in the lungs could be propagated to the joint. In study III, we set out to identify shared 
immunological targets in the lungs and joints of RA. 
We analyzed 7 synovial biopsies and 6 bronchial biopsies from RA patients using mass 
spectrometry to identify citrullinated proteins. We identified 5322 unique peptides and 1200 
proteins in the synovial and bronchial biopsies. With a MS/MS spectral identification score of 
at least 20, we were able to identify 10 citrullinated peptides corresponding to 7 proteins (table 
7). Of these, two citrullinated vimentin peptides were present in most of the samples: cit-Vim 
440-455 in all 7 synovial and 5 out of 6 bronchial biopsies, cit vim 446-466 in 6 out of 7 
synovial and in all 6 bronchial biopsies. A higher ratio of citrullinated/unmodified peptides was 
present in smokers compared to non-smokers. 
Using mass spectrometry, we were able to identify shared citrullinated peptides in the 
lungs and joints of RA patients. Identifying citrullination is challenging due to the very small 
mass shift of ~1 Da and to discriminate it from the frequently occurring deamidation with the 
same mass shift. Proteins such as Actin, Fibrinogen and Vimentin have been previously 
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suggested as immune targets in RA. However, in our samples only vimentin peptides were 
identified both in the lungs and joints. Due to the invasive sampling procedure, this study lacks 
paired synovial and bronchial samples from the same patient and control samples from healthy 
donors. 
 
Table 7: Quantification of citrullination in the lungs and joints of RA.  The values represent 
the corrected citrullinated/unmodified ratios in the lung and joint biopsies. ND denotes that 
neither citrullinated nor unmodified peptide was identified. NS and S implying non-smokers 
and smokers respectively. 0 is when only the native peptide was identified. 
 
We then aimed to investigate if a systemic immune response could be detected against 
the cit vimentin peptides that were present both in the lungs and the joints. In order to study 
that, we set up an in-house ELISA to analyze autoantibodies in the serum of RA. The two 
vimentin peptides that were identified by mass spectrometry were citrullinated at amino acid 
position 440 and 450. One peptide (vim 435-455) containing both the citrullinated amino acids 
were used to detect the citrulline-reactive antibodies in serum. 
Using a cohort of healthy volunteers, the cut-off for positivity for the ELISA was set at 
98th percentile of the reactivity. We analyzed serum from two RA cohorts and found 14.9% 
positive in the LURA cohort and 14.3% positive in the EIRA cohort. The disease controls 
displayed higher anti-citrulline positivity (3.4%) than the healthy controls (figure 11). Most of 
cit Vim 435-455 reactive sera was also anti-CCP2 positive (91.1%). Among the RA group, 
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85% of those displaying reactivity to cit vim 435-455 were HLA-DR SE positive. However, 
no association was found between smoking and the presence of antibodies against cit vim 435-
455. We also performed cross-reactivity ELISA in serum showing reactivity towards cit vim 
435-455 and other well studied vimentin epitopes namely cit vim 60-75. Although cross 
reactivity among ACPAs is not uncommon [162], we found that serum blocked with cit vim 
435-455 peptide did not interfere with reactivity against cit vim 60-75 suggesting no cross 
reactivity in patient serum that were tested. 
 
Figure 11: Antibodies against cit vim 435-455. Serum samples form Healthy controls, RA 
cohorts LURA and EIRA and Disease controls were analyzed for reactivity against cit vim 435-
455. The dotted line indicates the cut-off for the ELISA. The shaded portion of the pie charts 
represent the proportion of positive individuals in each group with the number in the middle 
indicating the sample size. 
 
Presence of citrullination in the lungs is not restricted to RA but can also be present in 
some healthy as well as COPD patients [40, 163]. One of the vimentin peptides containing 
citrulline at position 450 was also identified in lungs of COPD patients [163] and two of the 
healthy biopsies (data in paper III), while antibodies against these peptides were present only 
in RA (ELISA data) suggesting that other factors that might be present in RA, are required for 
immune response against citrullinated antigens. Our data demonstrate that the citrullinated 
peptides present both in the lungs and joints are indeed immunogenic eliciting a B cell response 
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and might possible be one of the ways by which antibodies potentially generated at the lungs 
find their targets in the joints causing inflammation. 
 
4.5 Systemic response to de novo identified citrullinated fibrinogen is associated with 
PTPN22 risk allele.   
Using an unbiased mass spectrometry approach, elevated levels of citrullinated 
fibrinogen peptides were identified in the synovial fluid of RA patients compared to disease 
controls [164]. In this study (IV), we aimed to analyze the immune reactivity against these de 
novo identified citrullinated fibrinogen alpha peptides. 
We intended to study if general B cell response against cit fibrinogen peptides existed, 
by analyzing the presence of antibodies. Using an in-house ELISA, we analyzed serum of RA 
patients and compared against healthy and disease controls (DC) that included patients with 
Psoriatic (PsA) and Spondylarthritis (SpA).  
 
 
Figure 12: Reactivity against different fibrinogen peptides in different cohorts. The bars 
chart represents the percent of positive reactivity in healthy (blue), RA (red) and disease 
controls (green). 
 
Using the 98th percent reactivity against healthy controls to set the cut off for the ELISA, 
we found 20.2% reactivity towards the cit-fib α 35, 12.5% towards cit-fib α 216,218, 21.0% 
towards cit-fib α 263,271 and 17.0% towards cit-fib α 425,426. The citrulline reactivity in the 
disease cohort was less than 1% for all the four peptides (figure 12). This confirms the presence 
of circulating antibodies against the citrullinated peptides, identified in the synovial fluid, and 
their occurrence being specific for RA.  
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Most of RA sera presented non-overlapping reactivity, with 106 samples (30.5%) 
displaying positivity to only one of the cit fibrinogen peptides, 48 (13.8%) to any of the two 
peptides, 12 (3.5%) to any of the three peptides and only two (0.6%) showing positivity to all 
4 cit peptides. The multiple reactivities could mean that either multiple autoantibody response 
could exist against different cit antigens or some degree of cross reactivity could occur the 
autoantibody response. More detailed studies and specific assays would be required to address 
this. 
Next, we analyzed the association between the reactivity against the different cit peptides 
and the two most studied genetic risk factors for RA, namely HLA-DR SE and PTPN22 
C1858T. Interestingly, no association was found between the HLA-DR SE (table 8) while an 
association and significant odds ratios was observed between PTPN22 C1858T and reactivity 
towards cit-fib α 35 and cit-fib α 263,271. This data suggests that the reactivity against some 
of the cit antigens might not entirely be dependent on the classical HLA-DR SE but might 
involve other autoimmune anomalies arising due to PTPN22. PTPN22 promotes the survival 
of autoreactive B cells in RA and type-1 diabetes by evading the tolerance checkpoints [20]. 
Additional factors as BAFF could also play a role in B cell activation and survival, but was not 
analyzed in this study. 
 
Table 8: Association between HLA-DR SE and PTPN22 C1858T and the different cit 
fibrinogen peptide reactivity. Columns one to three are results (chi-square test) for association 
and columns four and five are odds ratio for the presence of cit-fib antibodies in individuals 
with the different RA risk alleles. 
 
  
HLA-DR SE (326) 
No Yes p Value  OR (95% CI) p Value 
Cit-Fib α 35 11 (15.1) 55 (21.74) 0.21  1.6 (0.8-3.2) 0.21 
Cit-Fib α 216,218 12 (16.4) 30 (11.86) 0.30  0.7 (0.3-1.4) 0.31 
Cit-Fib α 263,271 13 (17.8) 57 (22.53) 0.39  1.3 (0.7-2.6) 0.39 
Cit-Fib α 425,426 10 (13.7) 46 (18.18) 0.37  1.4 (0.7-2.9) 0.37 
 
PTPN22 C1858T (322) 
No Yes p Value  OR (95% CI) p Value 
Cit-Fib α 35 38 (17.4) 28 (27.18) 0.04  1.8 (1-3.1) 0.04 
Cit-Fib α 216,218 32 (14.8) 9 (8.74) 0.14  0.6 (0.3-1.2) 0.14 
Cit-Fib α 263,271 39 (17.8) 30 (29.13) 0.02  2.0 (1.1-3.4) 0.02 
Cit-Fib α 425,426 34 (15.5) 23 (22.33) 0.14  1.6 (0.9-2.8) 0.14 
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Based on the data suggesting the role of PTPN22 C1858T allele carriers may have an 
inefficient peripheral tolerance, we hypothesized that the risk allele carriers in our cohort may 
have an expanded population of cit fibrinogen reactive B cells. We constructed cit fibrinogen 
antigen tetramers to identify such autoreactive B cells in risk allele carrier (CT) and non-allele 
carrier (CC) RA patients. We first analyzed frozen PBMCs from 5 RA patients (three CC and 
two CT) demonstrating a trend of increased frequency of cit fibrinogen tetramer positive B 
cells among the risk allele carriers. Further analysis of PBMCs from 10 RA patients (five CC 
and five CT) displayed the same trend.  
 
 
Figure 13. Cit fibrinogen reactive B cells identified using antigen tetramers. The upper panel 
represents the gating strategy to identify the tetramer positive B cells from PBMCs. The lower 
panel is the quantification of the tetramer positive B cells in a pilot and validation RA cohort. 
 
Using tetramer technology, we were able to identify the cit fibrinogen reactive B cells 
that were present in higher frequency among the PTPN22 risk allele carriers (figure 13). These 
results are in line with previous observation demonstrating increased autoreactive B cells 
among the PTPN22 risk allele carriers. Our data did not reach statistical significance which 
might depend on to the low number of patients included in the analysis. Sorting the tetramer 
positive B cells and sequencing and analyzing the immunoglobulin genes for germline or 
somatic mutations would have shed light on the T cell-dependent or independent origin of B 
cell activation/reactivity.  
  
CD	20
CD
	3
,	C
D	
14
,	C
D	
16
Cit Fib	Tetramer
De
co
y	T
et
ra
m
er
PE
	B
ou
nd
	F
ra
ct
io
n
Pilot	Cohort
(Frozen	Cells)
CC CT
0
50
100
150
Te
tr
am
er
+ 
ce
lls
 / 
10
6  b
 c
el
ls
 
Validation	Cohort
(Fresh	Cells)
CC CT
0
200
400
600
Te
tr
am
er
+ 
ce
lls
 / 
10
6  b
 c
el
ls
 
CD	19
CD
	2
0
  41 
5 CONCLUSION AND FUTURE PERSPECTIVES 
Through my thesis I aimed to fit in small pieces into the large puzzle, which is the 
understanding of the etiology and pathogenesis of RA. From being the secondary manifestation 
of RA, lungs have come into the spotlight and could instead be the origin of the disease, at least 
in some RA patients. 
In paper I, we investigated the relationship between the HRCT lung abnormalities and 
circulating ACPA fine specificities, where we found an association between some of the 
ACPAs and parenchymal abnormalities in early RA. More interestingly, the higher the number 
of ACPA fine specificities the higher were the odds of having parenchymal abnormalities. 
These findings suggest a potential role for the lungs in generation of these antibodies. In order 
to prove this, we are currently working to clone single B cells from the BAL fluid of ACPA 
positive RA patients as well as ACPA positive healthy individuals at risk for developing RA 
but not yet having joint inflammation. Another interesting aspect is the possibility that ACPA 
themselves are pathogenic and contribute to the observed lung abnormalities and this still 
remain to be elucidated in the future. In order to better investigate a causal role for the lung in 
RA we need to shift our studies towards earlier time points to include healthy individuals at 
risk for developing RA.  
In paper II, we examined the microbiome differences in early untreated RA and 
compared it with healthy individuals and sarcoidosis patients. From the study, we could 
conclude that dysbiosis exists in the lungs of early RA and is similar to that found in lung 
inflammatory condition such as Sarcoidosis. Like the previous study (paper I), this fails to 
address the causal relationship between the lung microbiome and the disease. This study would 
also benefit from studying individuals at risk of developing RA which is practically challenging 
due to the uncomfortable bronchoscopy procedure. Though some questions can be answered 
through studying induced sputum, these samples have a different bacterial relative abundance 
compared to that present in the lower airways. Another potential future development of the 
microbiome studies in RA could be use of probiotics in the treatment of the disease by 
modulating inflammation. Recent study in mice have demonstrated that Prevotella histicola, a 
commensal bacteria present in the human gut, had probiotic effect in attenuating arthritis in 
mice [165]. Additional studies are required to understand the role of the myriad of bacteria 
present in the lungs and gut and to find novel effective ways to interfere with it in order to 
attenuate inflammation.  
 42 
In paper III, we were able to identify shared citrullinated targets in the lungs and joints 
of RA patients and found immune reactivity against them. The results from this study could 
postulate that the immunity arising in the lungs are propagated via the circulation to the joints 
where they elicit their pathogenic roles. To understand the exact mechanisms that lead to the 
inflammatory joint manifestations, more studies are required to understand the triggering 
events and local changes in the lungs (and/or other mucosal surfaces) and how and when these 
changes ultimately lead to joint inflammation.  
In paper IV, we demonstrated that immune reactivity towards four de novo identified 
citrullinated fibrinogen peptides are present and specific for RA. We also demonstrated that the 
reactivity against some of these citrullinated fibrinogen peptides are associated to the PTPN22 
risk allele and not the HLA-DR. In addition, individuals with the PTPN22 risk allele tend to 
have higher frequency of citrullinated fibrinogen reactive B cells. We further demonstrated the 
use of B cell tetramer in identifying citrulline reactive B cells. Previous studies were able to 
isolated single B cells and clone citrulline reactive antibodies [166] and use them in vitro 
systems to study their effects [91]. Using B cell antigen tetramers would allow us to isolate 
such citrulline reactive B cells and to generate more specific antibodies and to understand their 
functional implications in RA. 
  
  43 
6 ACKNOWLEDGEMENTS 
This is where I get to thank all of you who have helped me and made this PhD journey an 
eventful and unforgettable experience. 
My main supervisor, Anca Catrina. Thank you for giving me the opportunity to do my PhD in 
your group. You have given me all the freedom that I could ever ask for, to explore new things, 
to study whatever I wanted, attend various conferences, and creating opportunities for me to 
develop as a researcher. You have always been an inspiration and working with you has been 
a good learning and very rewarding experience for me. Thank you for the retreats, Julbords, 
parties and for creating a wonderful working atmosphere.  
My co-supervisor, Vivianne Malmström. I could just walk to your desk any time when I had 
questions and you have always been welcoming. Thank you for putting up with me, letting me 
take chances, supporting my experimental ideas, helping me with manuscripts, encouraging 
me to review articles and for all the discussions I have had the opportunity to have with you. I 
could not have asked for anything more and I am truly thankful for this opportunity. 
My co-supervisor, Lars Klareskog. Thanks for your reply (on 2011 May 05) to my e-mail and 
for introducing me to Anca which led to this PhD. Thank you for building this truly 
international and wonderful atmosphere at the rheumatology unit and CMM. Your passion for 
science is contagious, your humility is admirable and you are always an inspiration. 
My co- supervisor, Heidi Wähämaa. Thanks for all your support throughout my PhD and this 
thesis. Thank you for the work with fibroblasts, microparticles, for introducing me to CBA, for 
running our first marathon, for the fishing trip and for keeping the group lively and fun. I cannot 
imagine our group without you. 
The head of the rheumatology unit, Ingrid Lundberg. Thank you for creating a very good 
atmosphere for research and encouraging interaction among different groups in the unit. 
My mentor Lalit Kumar, for giving me an opportunity to do my master’s thesis at your lab and 
for supporting me till this date, both professionally and personally. Thanks for the nice 
discussions, lunches and dinners at your place. 
All the members of Anca’s group, you have been great to work with and to hang around during 
conferences and retreats, our fun filled fika and lunches, meetings and discussion, I am grateful 
for all the support, help and inspiration. I cannot thank you all enough. Marianne E, for being 
kind and helpful throughout these years, for being a constant support and for the tasty sill that 
 44 
I get every Christmas. Gudrun R, for being a wonderful co-worker, collaborator and for the 
good times in Iceland.  Aase H, for the constant optimism and for inspiring curiosity.  Meng S 
(Sam), for all the support and fun, for the many muffins and for being my virtual guide during 
my trip to China. Katerina C, for the wonderful collaboration and discussion, and teaching me 
all that I know now about SPSS. Bence R for all the discussions (science and non-science) and 
talks. Jimmy Y for the mass spectrometry. Erik AK for letting me observe your clinics. Former 
and current members of the group Shankar R, Nancy V, Petra N, Yanying L, Alexandra C, 
Yogan K, Thank you! 
Alex E, Caroline G, Fredrik W, Karin L, Marina K, Marie WH and other senior researchers at 
the rheumatology unit for leading by example, for providing valuable inputs and being 
wonderful teachers. Leonid P for always being helpful with data and genotyping, nice 
discussions and for making me pant during badminton session. Helena EH for giving me the 
opportunity to be a part of the research school.  
All the collaborators at the Lung Lab, especially Johan G, Johan Ö, Jan W, for the wonderful 
collaboration. Susanna K, for showing me the bronchoscopy procedure. Benita D and Benita 
E, for the samples and Michael HJ for all the many favors for which I am indebted to you. 
Jose S and Leo S, co-authors at NYU. For the nice collaboration and giving me the opportunity 
to be in your lab. Other members of Leo’s (LNS) lab, Benjamin W, Yonghua L, Samuel C and 
Florian K for being kind and helpful during my time there. 
Johan R, for the discussions on ELISAs and cutoffs. All the other collaborators and co-authors, 
thank you! 
All the patients and healthy volunteers. None of this work would have been possible without 
your participation. 
All the current and former members of the B-cell group. Fiona M for the introducing me to the 
cloning world and helping me with the BAL project. Johanna S and Khaled S, for always 
helping me when I had questions and the nice talks. Phil T, for all the things that I know about 
tetramers and the long experiments that we did. Natalie S for the flow cytometry and fun while 
working together. 
Lena I and Monika H for the endless help and discussions on ELISA, ISAC, background, 
standards, cut-offs and analysis. Annika V, for always being helpful at the flow cytometry 
facility. Barbro L for the genotyping. Eva J, for all biobank help and samples throughout this 
thesis. Other members of the human lab Gloria R, Julia N and Susana H for your constant help. 
  45 
The research nurses at the rheumatology unit, especially Anna K and Seija J for helping me 
with patient samples. Stina N, for always being patient and helping me with all the 
administration work. And former members of the administration Gunnel B and Veronica EL. 
Current and former members at the rheumatology unit Eva L, Lena K, Lotta A, Louis B, 
Yvonne S, Peter S, Cecilia A, Lars O for the help with IT related things, Karine C for the 
discussion and chats, Sohel M, Sara B for inspiring persistence, the German trio Jessica H, Inka 
A and Christina G for all the wonderful times hanging out and fun, Joan R and Cátia C for good 
times during conferences and lunches, for the wonderful discussions and parties, Lina D, 
Angeles G, Sara T, Uta H, Johanna E for the nice talks, Jayesh P, Mei Z, Fari M for the 
microparticles project and all the others (that I have missed to name). Thank you! 
People I share my writing room with: Lara K for keeping the room lively, Hannah A, Vijole 
O, Nastya K and Natalia S, for the good times at conferences, Erwan LM, Raya S and Galina 
Z, it has been fun to share the space with you and thank you for the nice time. 
The research school (NCRSCID) for all the courses and activities. Agnes S, Daniëlle V, Eliane 
P, GudnyElla T, Joanna K, Jorge R, Karl C, Katerina N, Miranda H, Quan T, Rita I, Sandeep 
K and all the members of the research school for a wonderful experience during the school 
activities and lots of fun.  
Past and current members of the neuroimmunology unit that I have had the opportunity to 
interact. Brinda D for the lunches and parties, Mathias G for the nice talks and the many fun 
runs, André O, Harald L, Marie ND, Sabrina R, Susanne N, Tojo J, Srini R, Sevi F, Susanna B 
and all the others for being kind and for the nice talks. 
Member of my former lab (FRH lab) at KI, especially Kristina GD, Birgitta B for being kind, 
Sujatha LK for the nice talks and dinners at you place, Nage RB, Suby JV, Mo P. Thank you! 
My teachers from undergrad at KCT, thank you for believing in me and inspiring me to be 
better. My lifelong friends from then especially Bruce, Elango, Ganesh and Sri for reminding 
me about the important things in life.  
Judy aunty for welcoming me to Sweden, for packing me nice Indian food whenever you 
thought of me, Thank you ! 
To all my friends in Stockholm and those not in Stockholm any more, thanks for being there 
throughout this journey. You know who you are and I happy to have known you J ! 
 46 
Akilan, Vishnu, Prem, Priya, Sunil, Ramnath, Divya, Madhu, Priyanka, Vamsi, Gopi, Venkat: 
for all the barbeques, lunches, dinners, Diwali, Christmas and birthdays; for all the travelling 
we did together around the globe; for the badminton, volleyball, camping, board games, movies 
and bowling. I will cherish all those memories with you, plus 200GB of pictures J ! 
To people that I might have missed to mention. It was not intentional and hope you know that 
I appreciate and cherish the time we spent together and I am thankful for the things you have 
done for me. 
Growing up in a small town, getting here was a dream. This would not have been possible 
without the love and support of my family. My cousin Mercy for wonderful times we had and 
the endless support. My sister Vino, for being who you are, for sharing weird habits (we truly 
have the same genes), the times we spent fighting, having fun and for bringing brother-in-law 
Arun to our family. My Father, for everything I have, I am eternally grateful for all the sacrifices 
you have made for us. My Mother for all that I am today, especially for buying me story books 
at the book fair when we couldn’t afford it and for getting me started to dream. It all began 
there J.
  47 
7 REFERENCES 
1. Alamanos Y, Voulgari PV, Drosos AA: Incidence and prevalence of rheumatoid 
arthritis, based on the 1987 American College of Rheumatology criteria: a 
systematic review. Seminars in arthritis and rheumatism 2006, 36(3):182-188. 
2. van Vollenhoven RF: Sex differences in rheumatoid arthritis: more than meets 
the eye. BMC medicine 2009, 7:12. 
3. Entezami P, Fox DA, Clapham PJ, Chung KC: Historical perspective on the 
etiology of rheumatoid arthritis. Hand clinics 2011, 27(1):1-10. 
4. Yeap SS: Rheumatoid arthritis in paintings: a tale of two origins. International 
journal of rheumatic diseases 2009, 12(4):343-347. 
5. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA: Proposed diagnostic criteria 
for rheumatoid arthritis. Annals of the rheumatic diseases 1957, 16(1):118-125. 
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, 
Kaplan SR, Liang MH, Luthra HS et al: The American Rheumatism Association 
1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and 
rheumatism 1988, 31(3):315-324. 
7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum 
NS, Burmester GR, Bykerk VP, Cohen MD et al: 2010 Rheumatoid arthritis 
classification criteria: an American College of Rheumatology/European League 
Against Rheumatism collaborative initiative. Arthritis and rheumatism 2010, 
62(9):2569-2581. 
8. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis. An 
approach to understanding the molecular genetics of susceptibility to 
rheumatoid arthritis. Arthritis and rheumatism 1987, 30(11):1205-1213. 
9. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, Alfredsson L, 
Padyukov L, Klareskog L, Worthington J et al: Five amino acids in three HLA 
proteins explain most of the association between MHC and seropositive 
rheumatoid arthritis. Nature genetics 2012, 44(3):291-296. 
10. Scally SW, Petersen J, Law SC, Dudek NL, Nel HJ, Loh KL, Wijeyewickrema LC, 
Eckle SB, van Heemst J, Pike RN et al: A molecular basis for the association of the 
HLA-DRB1 locus, citrullination, and rheumatoid arthritis. The Journal of 
experimental medicine 2013, 210(12):2569-2582. 
11. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid 
J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S et al: A new model for an etiology 
of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-
restricted immune reactions to autoantigens modified by citrullination. Arthritis 
and rheumatism 2006, 54(1):38-46. 
12. Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, Pedersen 
BV, Wohlfahrt J, Frisch M: Strong combined gene-environment effects in anti-
cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-
control study in Denmark. Arthritis and rheumatism 2007, 56(5):1446-1453. 
13. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, 
MacMurray J, Meloni GF, Lucarelli P, Pellecchia M et al: A functional variant of 
 48 
lymphoid tyrosine phosphatase is associated with type I diabetes. Nature genetics 
2004, 36(4):337-338. 
14. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander 
HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM et al: A missense single-
nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase 
(PTPN22) is associated with rheumatoid arthritis. American journal of human 
genetics 2004, 75(2):330-337. 
15. Stanford SM, Bottini N: PTPN22: the archetypal non-HLA autoimmunity gene. 
Nature reviews Rheumatology 2014, 10(10):602-611. 
16. Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner 
JH: Genetic variation in PTPN22 corresponds to altered function of T and B 
lymphocytes. Journal of immunology 2007, 179(7):4704-4710. 
17. Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, Moon RT, Liggitt D, Wolf-
Yadlin A, Buckner JH et al: A disease-associated PTPN22 variant promotes 
systemic autoimmunity in murine models. The Journal of clinical investigation 
2013, 123(5):2024-2036. 
18. Salmond RJ, Brownlie RJ, Morrison VL, Zamoyska R: The tyrosine phosphatase 
PTPN22 discriminates weak self peptides from strong agonist TCR signals. 
Nature immunology 2014, 15(9):875-883. 
19. Habib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, 
Meyer-Bahlburg A, Sanda S, Greenbaum C et al: Altered B cell homeostasis is 
associated with type I diabetes and carriers of the PTPN22 allelic variant. 
Journal of immunology 2012, 188(1):487-496. 
20. Menard L, Saadoun D, Isnardi I, Ng YS, Meyers G, Massad C, Price C, Abraham C, 
Motaghedi R, Buckner JH et al: The PTPN22 allele encoding an R620W variant 
interferes with the removal of developing autoreactive B cells in humans. The 
Journal of clinical investigation 2011, 121(9):3635-3644. 
21. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van 
Mil AH, Toes RE, Huizinga TW, Klareskog L, Alfredsson L et al: Gene-gene and 
gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in 
two subsets of rheumatoid arthritis. American journal of human genetics 2007, 
80(5):867-875. 
22. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, 
Yoshida S et al: Genetics of rheumatoid arthritis contributes to biology and drug 
discovery. Nature 2014, 506(7488):376-381. 
23. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, 
Le JM, Lee HS, Batliwalla F et al: STAT4 and the risk of rheumatoid arthritis and 
systemic lupus erythematosus. The New England journal of medicine 2007, 
357(10):977-986. 
24. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, 
Khalili H, Chandrasekaran A, Davies LR et al: TRAF1-C5 as a risk locus for 
rheumatoid arthritis--a genomewide study. The New England journal of medicine 
2007, 357(12):1199-1209. 
25. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, 
Kastner DL, Alfredsson L, Altshuler D et al: Replication of putative candidate-
  49 
gene associations with rheumatoid arthritis in >4,000 samples from North 
America and Sweden: association of susceptibility with PTPN22, CTLA4, and 
PADI4. American journal of human genetics 2005, 77(6):1044-1060. 
26. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai 
S: Impact of smoking as a risk factor for developing rheumatoid arthritis: a 
meta-analysis of observational studies. Annals of the rheumatic diseases 2010, 
69(1):70-81. 
27. Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L, Alfredsson 
L, Group ES: Smoking is a major preventable risk factor for rheumatoid 
arthritis: estimations of risks after various exposures to cigarette smoke. Annals 
of the rheumatic diseases 2011, 70(3):508-511. 
28. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson 
L, group Es: Quantification of the influence of cigarette smoking on rheumatoid 
arthritis: results from a population based case-control study, using incident 
cases. Annals of the rheumatic diseases 2003, 62(9):835-841. 
29. Stolt P, Kallberg H, Lundberg I, Sjogren B, Klareskog L, Alfredsson L, group Es: 
Silica exposure is associated with increased risk of developing rheumatoid 
arthritis: results from the Swedish EIRA study. Annals of the rheumatic diseases 
2005, 64(4):582-586. 
30. Stolt P, Yahya A, Bengtsson C, Kallberg H, Ronnelid J, Lundberg I, Klareskog L, 
Alfredsson L, Group ES: Silica exposure among male current smokers is 
associated with a high risk of developing ACPA-positive rheumatoid arthritis. 
Annals of the rheumatic diseases 2010, 69(6):1072-1076. 
31. Too CL, Muhamad NA, Ilar A, Padyukov L, Alfredsson L, Klareskog L, Murad S, 
Bengtsson C, My ESG: Occupational exposure to textile dust increases the risk of 
rheumatoid arthritis: results from a Malaysian population-based case-control 
study. Annals of the rheumatic diseases 2016, 75(6):997-1002. 
32. Hart JE, Kallberg H, Laden F, Costenbader KH, Yanosky JD, Klareskog L, 
Alfredsson L, Karlson EW: Ambient air pollution exposures and risk of 
rheumatoid arthritis. Arthritis care & research 2013, 65(7):1190-1196. 
33. Hart JE, Kallberg H, Laden F, Bellander T, Costenbader KH, Holmqvist M, 
Klareskog L, Alfredsson L, Karlson EW: Ambient air pollution exposures and risk 
of rheumatoid arthritis: results from the Swedish EIRA case-control study. 
Annals of the rheumatic diseases 2013, 72(6):888-894. 
34. Hart JE, Laden F, Puett RC, Costenbader KH, Karlson EW: Exposure to traffic 
pollution and increased risk of rheumatoid arthritis. Environmental health 
perspectives 2009, 117(7):1065-1069. 
35. Bicker KL, Thompson PR: The protein arginine deiminases: Structure, function, 
inhibition, and disease. Biopolymers 2013, 99(2):155-163. 
36. McGraw WT, Potempa J, Farley D, Travis J: Purification, characterization, and 
sequence analysis of a potential virulence factor from Porphyromonas gingivalis, 
peptidylarginine deiminase. Infection and immunity 1999, 67(7):3248-3256. 
37. Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI: Citrullination: a posttranslational 
modification in health and disease. The international journal of biochemistry & cell 
biology 2006, 38(10):1662-1677. 
 50 
38. Neeli I, Khan SN, Radic M: Histone deimination as a response to inflammatory 
stimuli in neutrophils. Journal of immunology 2008, 180(3):1895-1902. 
39. Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog L, 
Catrina AI: Citrullination is an inflammation-dependent process. Annals of the 
rheumatic diseases 2006, 65(9):1219-1222. 
40. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund 
A, Grunewald J, Skold CM, Klareskog L, Catrina AI: Smoking increases 
peptidylarginine deiminase 2 enzyme expression in human lungs and increases 
citrullination in BAL cells. Annals of the rheumatic diseases 2008, 67(10):1488-
1492. 
41. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G: 
The antiperinuclear factor and the so-called antikeratin antibodies are the same 
rheumatoid arthritis-specific autoantibodies. The Journal of clinical investigation 
1995, 95(6):2672-2679. 
42. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij 
WJ: Citrulline is an essential constituent of antigenic determinants recognized by 
rheumatoid arthritis-specific autoantibodies. The Journal of clinical investigation 
1998, 101(1):273-281. 
43. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP: The 
presence of citrullinated proteins is not specific for rheumatoid synovial tissue. 
Arthritis and rheumatism 2004, 50(11):3485-3494. 
44. Reynisdottir G, Karimi R, Joshua V, Olsen H, Hensvold AH, Harju A, Engstrom M, 
Grunewald J, Nyren S, Eklund A et al: Structural changes and antibody 
enrichment in the lungs are early features of anti-citrullinated protein antibody-
positive rheumatoid arthritis. Arthritis & rheumatology 2014, 66(1):31-39. 
45. Makrygiannakis D, Revu S, Engstrom M, af Klint E, Nicholas AP, Pruijn GJ, Catrina 
AI: Local administration of glucocorticoids decreases synovial citrullination in 
rheumatoid arthritis. Arthritis research & therapy 2012, 14(1):R20. 
46. Trouw LA, Rispens T, Toes REM: Beyond citrullination: other post-translational 
protein modifications in rheumatoid arthritis. Nature reviews Rheumatology 2017, 
13(6):331-339. 
47. Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, Toes RE, 
Trouw LA: Carbamylation and antibodies against carbamylated proteins in 
autoimmunity and other pathologies. Autoimmunity reviews 2014, 13(3):225-230. 
48. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, 
Levarht NE, van der Helm-van Mil AH, Cerami A, Huizinga TW et al: 
Autoantibodies recognizing carbamylated proteins are present in sera of patients 
with rheumatoid arthritis and predict joint damage. Proceedings of the National 
Academy of Sciences of the United States of America 2011, 108(42):17372-17377. 
49. Reed E, Jiang X, Kharlamova N, Ytterberg AJ, Catrina AI, Israelsson L, Mathsson-
Alm L, Hansson M, Alfredsson L, Ronnelid J et al: Antibodies to carbamylated 
alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes 
and are largely indistinct from anti-citrullinated protein antibodies. Arthritis 
research & therapy 2016, 18(1):96. 
  51 
50. Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Kallberg H, Malmstrom 
V, Israelsson L, Hreggvidsdottir H, Verduijn W et al: Anti-CarP antibodies in two 
large cohorts of patients with rheumatoid arthritis and their relationship to 
genetic risk factors, cigarette smoking and other autoantibodies. Annals of the 
rheumatic diseases 2014, 73(10):1761-1768. 
51. Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, Bokarewa M: 
Carbamylation-dependent activation of T cells: a novel mechanism in the 
pathogenesis of autoimmune arthritis. Journal of immunology 2010, 184(12):6882-
6890. 
52. Ospelt C, Bang H, Feist E, Camici G, Keller S, Detert J, Kramer A, Gay S, Ghannam 
K, Burmester GR: Carbamylation of vimentin is inducible by smoking and 
represents an independent autoantigen in rheumatoid arthritis. Annals of the 
rheumatic diseases 2017, 76(7):1176-1183. 
53. Yang XJ, Seto E: Lysine acetylation: codified crosstalk with other 
posttranslational modifications. Molecular cell 2008, 31(4):449-461. 
54. Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, Buckley CD, Fisher 
B, Filer A, Raza K: Identification of novel antiacetylated vimentin antibodies in 
patients with early inflammatory arthritis. Annals of the rheumatic diseases 2016, 
75(6):1099-1107. 
55. Gronwall C, Amara K, Hardt U, Krishnamurthy A, Steen J, Engstrom M, Sun M, 
Ytterberg AJ, Zubarev RA, Scheel-Toellner D et al: Autoreactivity to 
malondialdehyde-modifications in rheumatoid arthritis is linked to disease 
activity and synovial pathogenesis. Journal of autoimmunity 2017. 
56. Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, 
Kleyer A, Reiser M, Finzel S et al: Antimodified protein antibody response 
pattern influences the risk for disease relapse in patients with rheumatoid 
arthritis tapering disease modifying antirheumatic drugs. Annals of the rheumatic 
diseases 2017, 76(2):399-407. 
57. Waaler E: On the occurrence of a factor in human serum activating the specific 
agglutintion of sheep blood corpuscles. 1939. APMIS : acta pathologica, 
microbiologica, et immunologica Scandinavica 2007, 115(5):422-438; discussion 
439. 
58. Pike RM, Sulkin SE, Coggeshall HC: Serological reactions in rheumatoid 
arthritis; factors affecting the agglutination of sensitized sheep erythrocytes in 
rheumatid-arthritis serum. J Immunol 1949, 63(4):441-446. 
59. Zuraw BL, O'Hair CH, Vaughan JH, Mathison DA, Curd JG, Katz DH: 
Immunoglobulin E-rheumatoid factor in the serum of patients with rheumatoid 
arthritis, asthma, and other diseases. The Journal of clinical investigation 1981, 
68(6):1610-1613. 
60. Teitsson I, Withrington RH, Seifert MH, Valdimarsson H: Prospective study of 
early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor. Annals 
of the rheumatic diseases 1984, 43(5):673-678. 
61. Ingegnoli F, Castelli R, Gualtierotti R: Rheumatoid factors: clinical applications. 
Disease markers 2013, 35(6):727-734. 
 52 
62. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, 
Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and 
IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis 
and rheumatism 2003, 48(10):2741-2749. 
63. Arnason JA, Jonsson T, Brekkan A, Sigurjonsson K, Valdimarsson H: Relation 
between bone erosions and rheumatoid factor isotypes. Annals of the rheumatic 
diseases 1987, 46(5):380-384. 
64. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns 
B, Vincent C, Mielants H et al: Rheumatoid factor and anticitrullinated protein 
antibodies in rheumatoid arthritis: diagnostic value, associations with 
radiological progression rate, and extra-articular manifestations. Annals of the 
rheumatic diseases 2004, 63(12):1587-1593. 
65. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld 
FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis 
antibodies recognizing a cyclic citrullinated peptide. Arthritis and rheumatism 
2000, 43(1):155-163. 
66. van Gaalen FA, Visser H, Huizinga TW: A comparison of the diagnostic accuracy 
and prognostic value of the first and second anti-cyclic citrullinated peptides 
(CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Annals of the 
rheumatic diseases 2005, 64(10):1510-1512. 
67. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu 
T, Serre G: The major synovial targets of the rheumatoid arthritis-specific 
antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains 
of fibrin. J Immunol 2001, 166(6):4177-4184. 
68. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van 
Venrooij WJ, Menard HA: Rheumatoid arthritis specific anti-Sa antibodies target 
citrullinated vimentin. Arthritis research & therapy 2004, 6(2):R142-150. 
69. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D, Taylor 
PC, Venables PJ: Identification of citrullinated alpha-enolase as a candidate 
autoantigen in rheumatoid arthritis. Arthritis research & therapy 2005, 
7(6):R1421-1429. 
70. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R: 
Humoral immune response to citrullinated collagen type II determinants in early 
rheumatoid arthritis. European journal of immunology 2005, 35(5):1643-1652. 
71. Pratesi F, Dioni I, Tommasi C, Alcaro MC, Paolini I, Barbetti F, Boscaro F, Panza F, 
Puxeddu I, Rovero P et al: Antibodies from patients with rheumatoid arthritis 
target citrullinated histone 4 contained in neutrophils extracellular traps. Annals 
of the rheumatic diseases 2014, 73(7):1414-1422. 
72. Schwenzer A, Jiang X, Mikuls TR, Payne JB, Sayles HR, Quirke AM, Kessler BM, 
Fischer R, Venables PJ, Lundberg K et al: Identification of an immunodominant 
peptide from citrullinated tenascin-C as a major target for autoantibodies in 
rheumatoid arthritis. Annals of the rheumatic diseases 2016, 75(10):1876-1883. 
73. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, Oosterink E, Bozic B, Pruijn 
GJ: The rheumatoid arthritis synovial fluid citrullinome reveals novel 
citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation 
antigen, and beta-actin. Arthritis and rheumatism 2013, 65(1):69-80. 
  53 
74. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay 
A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE: Isotype 
distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated 
arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis 
and rheumatism 2006, 54(12):3799-3808. 
75. van der Woude D, Syversen SW, van der Voort EI, Verpoort KN, Goll GL, van der 
Linden MP, van der Helm-van Mil AH, van der Heijde DM, Huizinga TW, Kvien TK 
et al: The ACPA isotype profile reflects long-term radiographic progression in 
rheumatoid arthritis. Annals of the rheumatic diseases 2010, 69(6):1110-1116. 
76. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-
Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA: 
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of 
serial measurements in blood donors. Arthritis and rheumatism 2004, 50(2):380-
386. 
77. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW: 
Antibodies to citrullinated proteins and differences in clinical progression of 
rheumatoid arthritis. Arthritis research & therapy 2005, 7(5):R949-958. 
78. Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G: 
Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on 
bone erosions in patients with RA. Annals of the rheumatic diseases 2015, 
74(12):2151-2156. 
79. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, Edison JD, 
Gilliland WR, Tibshirani RJ, Norris JM et al: Autoantibody epitope spreading in 
the pre-clinical phase predicts progression to rheumatoid arthritis. PloS one 
2012, 7(5):e35296. 
80. Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, Stenlund 
H, Ronnelid J, Klareskog L, Rantapaa-Dahlqvist S: Multiplex analyses of antibodies 
against citrullinated peptides in individuals prior to development of rheumatoid 
arthritis. Arthritis and rheumatism 2013, 65(4):899-910. 
81. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers 
VM: Antibodies against citrullinated proteins enhance tissue injury in 
experimental autoimmune arthritis. The Journal of clinical investigation 2006, 
116(4):961-973. 
82. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G: 
Induction of macrophage secretion of tumor necrosis factor alpha through 
Fcgamma receptor IIa engagement by rheumatoid arthritis-specific 
autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis and 
rheumatism 2008, 58(3):678-688. 
83. Sokolove J, Zhao X, Chandra PE, Robinson WH: Immune complexes containing 
citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and 
Fcgamma receptor. Arthritis and rheumatism 2011, 63(1):53-62. 
84. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, 
Huizinga TW, Toes RE: Anti-cyclic citrullinated peptide antibodies from 
rheumatoid arthritis patients activate complement via both the classical and 
alternative pathways. Arthritis and rheumatism 2009, 60(7):1923-1931. 
 54 
85. Lu MC, Lai NS, Yu HC, Huang HB, Hsieh SC, Yu CL: Anti-citrullinated protein 
antibodies bind surface-expressed citrullinated Grp78 on 
monocyte/macrophages and stimulate tumor necrosis factor alpha production. 
Arthritis and rheumatism 2010, 62(5):1213-1223. 
86. Lu MC, Lai NS, Yin WY, Yu HC, Huang HB, Tung CH, Huang KY, Yu CL: Anti-
citrullinated protein antibodies activated ERK1/2 and JNK mitogen-activated 
protein kinases via binding to surface-expressed citrullinated GRP78 on 
mononuclear cells. Journal of clinical immunology 2013, 33(3):558-566. 
87. Sato Y, Sato R, Watanabe H, Kogure A, Watanabe K, Nishimaki T, Kasukawa R, 
Kuraya M, Fujita T: Complement activating properties of monoreactive and 
polyreactive IgM rheumatoid factors. Annals of the rheumatic diseases 1993, 
52(11):795-800. 
88. Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, Pasquali JL, 
Sebbag M, Serre G: IgM rheumatoid factor amplifies the inflammatory response 
of macrophages induced by the rheumatoid arthritis-specific immune complexes 
containing anticitrullinated protein antibodies. Annals of the rheumatic diseases 
2015, 74(7):1425-1431. 
89. Anquetil F, Clavel C, Offer G, Serre G, Sebbag M: IgM and IgA rheumatoid 
factors purified from rheumatoid arthritis sera boost the Fc receptor- and 
complement-dependent effector functions of the disease-specific anti-
citrullinated protein autoantibodies. J Immunol 2015, 194(8):3664-3674. 
90. Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruhbeisser S, Amara K, Bang H, Lux A, 
Koeleman CA, Baum W et al: Glycosylation of immunoglobulin G determines 
osteoclast differentiation and bone loss. Nature communications 2015, 6:6651. 
91. Krishnamurthy A, Joshua V, Haj Hensvold A, Jin T, Sun M, Vivar N, Ytterberg AJ, 
Engstrom M, Fernandes-Cerqueira C, Amara K et al: Identification of a novel 
chemokine-dependent molecular mechanism underlying rheumatoid arthritis-
associated autoantibody-mediated bone loss. Annals of the rheumatic diseases 
2016, 75(4):721-729. 
92. Wigerblad G, Bas DB, Fernades-Cerqueira C, Krishnamurthy A, Nandakumar KS, 
Rogoz K, Kato J, Sandor K, Su J, Jimenez-Andrade JM et al: Autoantibodies to 
citrullinated proteins induce joint pain independent of inflammation via a 
chemokine-dependent mechanism. Annals of the rheumatic diseases 2016, 
75(4):730-738. 
93. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, 
Tak PP, van de Stadt RJ, van der Laken CJ, Dijkmans BA et al: Arthritis 
development in patients with arthralgia is strongly associated with anti-
citrullinated protein antibody status: a prospective cohort study. Annals of the 
rheumatic diseases 2010, 69(3):490-494. 
94. van Steenbergen HW, Mangnus L, Reijnierse M, Huizinga TW, van der Helm-van 
Mil AH: Clinical factors, anticitrullinated peptide antibodies and MRI-detected 
subclinical inflammation in relation to progression from clinically suspect 
arthralgia to arthritis. Annals of the rheumatic diseases 2016, 75(10):1824-1830. 
95. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J, Early 
Rheumatoid Arthritis Study g: Mortality in rheumatoid arthritis. Increased in the 
early course of disease, in ischaemic heart disease and in pulmonary fibrosis. 
Rheumatology 2007, 46(2):350-357. 
  55 
96. Kelmenson LB, Demoruelle MK, Deane KD: The Complex Role of the Lung in the 
Pathogenesis and Clinical Outcomes of Rheumatoid Arthritis. Current 
rheumatology reports 2016, 18(11):69. 
97. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, 
Vassallo R, Gabriel SE, Matteson EL: Incidence and mortality of interstitial lung 
disease in rheumatoid arthritis: a population-based study. Arthritis and 
rheumatism 2010, 62(6):1583-1591. 
98. Wilsher M, Voight L, Milne D, Teh M, Good N, Kolbe J, Williams M, Pui K, 
Merriman T, Sidhu K et al: Prevalence of airway and parenchymal abnormalities 
in newly diagnosed rheumatoid arthritis. Respiratory medicine 2012, 
106(10):1441-1446. 
99. Mori S, Cho I, Koga Y, Sugimoto M: Comparison of pulmonary abnormalities on 
high-resolution computed tomography in patients with early versus longstanding 
rheumatoid arthritis. The Journal of rheumatology 2008, 35(8):1513-1521. 
100. Mori S, Koga Y, Sugimoto M: Different risk factors between interstitial lung 
disease and airway disease in rheumatoid arthritis. Respiratory medicine 2012, 
106(11):1591-1599. 
101. Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, Siegelman 
S, Connors G, Robinson WH, Bathon JM: Association of fine specificity and 
repertoire expansion of anticitrullinated peptide antibodies with rheumatoid 
arthritis associated interstitial lung disease. Annals of the rheumatic diseases 2014, 
73(8):1487-1494. 
102. Giles JT, Darrah E, Danoff S, Johnson C, Andrade F, Rosen A, Bathon JM: 
Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 
and 4 with rheumatoid arthritis-associated interstitial lung disease. PloS one 
2014, 9(6):e98794. 
103. Reynisdottir G, Olsen H, Joshua V, Engstrom M, Forsslund H, Karimi R, Skold CM, 
Nyren S, Eklund A, Grunewald J et al: Signs of immune activation and local 
inflammation are present in the bronchial tissue of patients with untreated early 
rheumatoid arthritis. Annals of the rheumatic diseases 2016, 75(9):1722-1727. 
104. Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish MC, Pedraza IF, 
Weisman MH, Norris JM, Holers VM, Deane KD: Sputum autoantibodies in 
patients with established rheumatoid arthritis and subjects at risk of future 
clinically apparent disease. Arthritis and rheumatism 2013, 65(10):2545-2554. 
105. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD: 
Inducible bronchus-associated lymphoid tissue (iBALT) in patients with 
pulmonary complications of rheumatoid arthritis. The Journal of clinical 
investigation 2006, 116(12):3183-3194. 
106. Thursby E, Juge N: Introduction to the human gut microbiota. The Biochemical 
journal 2017, 474(11):1823-1836. 
107. Sender R, Fuchs S, Milo R: Revised Estimates for the Number of Human and 
Bacteria Cells in the Body. PLoS biology 2016, 14(8):e1002533. 
108. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, 
Nelson KE, Relman DA: Diversity of the human intestinal microbial flora. Science 
2005, 308(5728):1635-1638. 
 56 
109. Scher JU, Abramson SB: The microbiome and rheumatoid arthritis. Nature 
reviews Rheumatology 2011, 7(10):569-578. 
110. Human Microbiome Project C: Structure, function and diversity of the healthy 
human microbiome. Nature 2012, 486(7402):207-214. 
111. Hooper LV, Macpherson AJ: Immune adaptations that maintain homeostasis with 
the intestinal microbiota. Nature reviews Immunology 2010, 10(3):159-169. 
112. Gu S, Chen D, Zhang JN, Lv X, Wang K, Duan LP, Nie Y, Wu XL: Bacterial 
community mapping of the mouse gastrointestinal tract. PloS one 2013, 
8(10):e74957. 
113. Marietta E, Rishi A, Taneja V: Immunogenetic control of the intestinal 
microbiota. Immunology 2015, 145(3):313-322. 
114. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin 
ML, Jones WJ, Roe BA, Affourtit JP et al: A core gut microbiome in obese and 
lean twins. Nature 2009, 457(7228):480-484. 
115. Costello ME, Ciccia F, Willner D, Warrington N, Robinson PC, Gardiner B, Marshall 
M, Kenna TJ, Triolo G, Brown MA: Brief Report: Intestinal Dysbiosis in 
Ankylosing Spondylitis. Arthritis & rheumatology 2015, 67(3):686-691. 
116. Morgan XC, Kabakchiev B, Waldron L, Tyler AD, Tickle TL, Milgrom R, Stempak 
JM, Gevers D, Xavier RJ, Silverberg MS et al: Associations between host gene 
expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of 
patients with inflammatory bowel disease. Genome biology 2015, 16:67. 
117. Mejia-Leon ME, Petrosino JF, Ajami NJ, Dominguez-Bello MG, de la Barca AM: 
Fecal microbiota imbalance in Mexican children with type 1 diabetes. Scientific 
reports 2014, 4:3814. 
118. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D et al: A 
metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 
2012, 490(7418):55-60. 
119. Shinebaum R, Neumann VC, Cooke EM, Wright V: Comparison of faecal florae in 
patients with rheumatoid arthritis and controls. British journal of rheumatology 
1987, 26(5):329-333. 
120. Eerola E, Mottonen T, Hannonen P, Luukkainen R, Kantola I, Vuori K, Tuominen J, 
Toivanen P: Intestinal flora in early rheumatoid arthritis. British journal of 
rheumatology 1994, 33(11):1030-1038. 
121. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, 
Cerundolo V, Pamer EG, Abramson SB et al: Expansion of intestinal Prevotella 
copri correlates with enhanced susceptibility to arthritis. eLife 2013, 2:e01202. 
122. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y et al: 
The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly 
normalized after treatment. Nature medicine 2015, 21(8):895-905. 
123. Kohashi O, Kohashi Y, Takahashi T, Ozawa A, Shigematsu N: Reverse effect of 
gram-positive bacteria vs. gram-negative bacteria on adjuvant-induced arthritis 
in germfree rats. Microbiology and immunology 1985, 29(6):487-497. 
  57 
124. Wu HJ, Ivanov, II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, 
Mathis D: Gut-residing segmented filamentous bacteria drive autoimmune 
arthritis via T helper 17 cells. Immunity 2010, 32(6):815-827. 
125. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake 
TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F et al: Stimulation 
of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model 
of arthritis. The Journal of clinical investigation 2008, 118(1):205-216. 
126. Sampaio-Maia B, Caldas IM, Pereira ML, Perez-Mongiovi D, Araujo R: The Oral 
Microbiome in Health and Its Implication in Oral and Systemic Diseases. 
Advances in applied microbiology 2016, 97:171-210. 
127. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ: Periodontitis in RA-the 
citrullinated enolase connection. Nature reviews Rheumatology 2010, 6(12):727-
730. 
128. Konig MF, Abusleme L, Reinholdt J, Palmer RJ, Teles RP, Sampson K, Rosen A, 
Nigrovic PA, Sokolove J, Giles JT et al: Aggregatibacter actinomycetemcomitans-
induced hypercitrullination links periodontal infection to autoimmunity in 
rheumatoid arthritis. Science translational medicine 2016, 8(369):369ra176. 
129. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, Bushman FD, 
Collman RG: Topographical continuity of bacterial populations in the healthy 
human respiratory tract. Am J Respir Crit Care Med 2011, 184(8):957-963. 
130. Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, 
Bushman FD, Collman RG: Disordered microbial communities in the upper 
respiratory tract of cigarette smokers. PloS one 2010, 5(12):e15216. 
131. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, 
Beck JM, Curtis JL, Huffnagle GB: Analysis of the upper respiratory tract 
microbiotas as the source of the lung and gastric microbiotas in healthy 
individuals. mBio 2015, 6(2):e00037. 
132. Wu BG, Segal LN: Lung Microbiota and Its Impact on the Mucosal Immune 
Phenotype. Microbiology spectrum 2017, 5(3). 
133. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt 
LA, Young VB, Toews GB, Curtis JL, Sundaram B et al: Analysis of the lung 
microbiome in the "healthy" smoker and in COPD. PloS one 2011, 6(2):e16384. 
134. Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, Flores SC, 
Fontenot AP, Ghedin E, Huang L et al: Comparison of the respiratory microbiome 
in healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013, 
187(10):1067-1075. 
135. Sze MA, Dimitriu PA, Suzuki M, McDonough JE, Campbell JD, Brothers JF, Erb-
Downward JR, Huffnagle GB, Hayashi S, Elliott WM et al: Host Response to the 
Lung Microbiome in Chronic Obstructive Pulmonary Disease. Am J Respir Crit 
Care Med 2015, 192(4):438-445. 
136. Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DF, Arron JR, Boushey H: The 
airway microbiome in patients with severe asthma: Associations with disease 
features and severity. The Journal of allergy and clinical immunology 2015, 
136(4):874-884. 
 58 
137. Hensvold AH, Magnusson PK, Joshua V, Hansson M, Israelsson L, Ferreira R, 
Jakobsson PJ, Holmdahl R, Hammarstrom L, Malmstrom V et al: Environmental 
and genetic factors in the development of anticitrullinated protein antibodies 
(ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological 
investigation in twins. Annals of the rheumatic diseases 2015, 74(2):375-380. 
138. Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Ronnelid J, Rantapaa-
Dahlqvist S: Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated 
peptide precede the development of rheumatoid arthritis. Arthritis research & 
therapy 2011, 13(1):R13. 
139. Brink M, Hansson M, Mathsson-Alm L, Wijayatunga P, Verheul MK, Trouw LA, 
Holmdahl R, Ronnelid J, Klareskog L, Rantapaa-Dahlqvist S: Rheumatoid factor 
isotypes in relation to antibodies against citrullinated peptides and carbamylated 
proteins before the onset of rheumatoid arthritis. Arthritis research & therapy 
2016, 18:43. 
140. Dye JA, Adler KB: Effects of cigarette smoke on epithelial cells of the respiratory 
tract. Thorax 1994, 49(8):825-834. 
141. Aoshiba K, Tamaoki J, Nagai A: Acute cigarette smoke exposure induces 
apoptosis of alveolar macrophages. American journal of physiology Lung cellular 
and molecular physiology 2001, 281(6):L1392-1401. 
142. Stampfli MR, Anderson GP: How cigarette smoke skews immune responses to 
promote infection, lung disease and cancer. Nature reviews Immunology 2009, 
9(5):377-384. 
143. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI: Cigarette 
smoke induces interleukin-8 release from human bronchial epithelial cells. Am J 
Respir Crit Care Med 1997, 155(5):1770-1776. 
144. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, 
Knight JS, Friday S, Li S, Patel RM, Subramanian V et al: NETs are a source of 
citrullinated autoantigens and stimulate inflammatory responses in rheumatoid 
arthritis. Science translational medicine 2013, 5(178):178ra140. 
145. Bidkar M, Vassallo R, Luckey D, Smart M, Mouapi K, Taneja V: Cigarette Smoke 
Induces Immune Responses to Vimentin in both, Arthritis-Susceptible and -
Resistant Humanized Mice. PloS one 2016, 11(9):e0162341. 
146. van de Stadt LA, van der Horst AR, de Koning MH, Bos WH, Wolbink GJ, van de 
Stadt RJ, Pruijn GJ, Dijkmans BA, van Schaardenburg D, Hamann D: The extent of 
the anti-citrullinated protein antibody repertoire is associated with arthritis 
development in patients with seropositive arthralgia. Annals of the rheumatic 
diseases 2011, 70(1):128-133. 
147. Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, Araujo E, Hueber AJ, 
Harre U, Engelke K et al: Bone loss before the clinical onset of rheumatoid 
arthritis in subjects with anticitrullinated protein antibodies. Annals of the 
rheumatic diseases 2014, 73(5):854-860. 
148. Malmstrom V, Catrina AI, Klareskog L: The immunopathogenesis of seropositive 
rheumatoid arthritis: from triggering to targeting. Nature reviews Immunology 
2017, 17(1):60-75. 
  59 
149. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, Engstrom A, 
Venables PJ, Lundeberg J, Holmdahl R et al: Multiple antibody reactivities to 
citrullinated antigens in sera from patients with rheumatoid arthritis: 
association with HLA-DRB1 alleles. Annals of the rheumatic diseases 2009, 
68(5):736-743. 
150. Snir O, Gomez-Cabrero D, Montes A, Perez-Pampin E, Gomez-Reino JJ, 
Seddighzadeh M, Klich KU, Israelsson L, Ding B, Catrina AI et al: Non-HLA genes 
PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-
defined subgroups of rheumatoid arthritis. Arthritis research & therapy 2014, 
16(4):414. 
151. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen 
GL, Knight R, Hugenholtz P: An improved Greengenes taxonomy with explicit 
ranks for ecological and evolutionary analyses of bacteria and archaea. Isme J 
2012, 6(3):610-618. 
152. Taylor JJ, Martinez RJ, Titcombe PJ, Barsness LO, Thomas SR, Zhang N, Katzman 
SD, Jenkins MK, Mueller DL: Deletion and anergy of polyclonal B cells specific 
for ubiquitous membrane-bound self-antigen. The Journal of experimental 
medicine 2012, 209(11):2065-2077. 
153. Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, 
Huie TJ, Stevens AD, Gill MB, Rabinovitch AM et al: Lung disease with anti-CCP 
antibodies but not rheumatoid arthritis or connective tissue disease. Respiratory 
medicine 2012, 106(7):1040-1047. 
154. Ossipova E, Cerqueira CF, Reed E, Kharlamova N, Israelsson L, Holmdahl R, 
Nandakumar KS, Engstrom M, Harre U, Schett G et al: Affinity purified anti-
citrullinated protein/peptide antibodies target antigens expressed in the 
rheumatoid joint. Arthritis research & therapy 2014, 16(4):R167. 
155. Perez T, Remy-Jardin M, Cortet B: Airways involvement in rheumatoid arthritis: 
clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998, 157(5 
Pt 1):1658-1665. 
156. Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, 
Harrington AR, Kolfenbach JR, Striebich CC, Pham QN et al: Brief report: airways 
abnormalities and rheumatoid arthritis-related autoantibodies in subjects 
without arthritis: early injury or initiating site of autoimmunity? Arthritis and 
rheumatism 2012, 64(6):1756-1761. 
157. Wolfe F, Caplan L, Michaud K: Treatment for rheumatoid arthritis and the risk 
of hospitalization for pneumonia: associations with prednisone, disease-
modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis 
and rheumatism 2006, 54(2):628-634. 
158. Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Nelson H, Matteson 
EL, Taneja V: An expansion of rare lineage intestinal microbes characterizes 
rheumatoid arthritis. Genome medicine 2016, 8(1):43. 
159. Sen R, Ishak HD, Estrada D, Dowd SE, Hong E, Mueller UG: Generalized 
antifungal activity and 454-screening of Pseudonocardia and Amycolatopsis 
bacteria in nests of fungus-growing ants. Proceedings of the National Academy of 
Sciences of the United States of America 2009, 106(42):17805-17810. 
 60 
160. Reynisdottir G, Olsen H, Joshua V, Engstrom M, Forsslund H, Karimi R, Skold CM, 
Nyren S, Eklund A, Grunewald J et al: Signs of immune activation and local 
inflammation are present in the bronchial tissue of patients with untreated early 
rheumatoid arthritis. Annals of the rheumatic diseases 2016, 75(9):1722-1727. 
161. Catrina AI, Joshua V, Klareskog L, Malmstrom V: Mechanisms involved in 
triggering rheumatoid arthritis. Immunological reviews 2016, 269(1):162-174. 
162. Goules JD, Goules AV, Tzioufas AG: Fine specificity of anti-citrullinated peptide 
antibodies discloses a heterogeneous antibody population in rheumatoid 
arthritis. Clinical and experimental immunology 2013, 174(1):10-17. 
163. Lugli EB, Correia RE, Fischer R, Lundberg K, Bracke KR, Montgomery AB, Kessler 
BM, Brusselle GG, Venables PJ: Expression of citrulline and homocitrulline 
residues in the lungs of non-smokers and smokers: implications for 
autoimmunity in rheumatoid arthritis. Arthritis research & therapy 2015, 17:9. 
164. Raijmakers R, van Beers JJ, El-Azzouny M, Visser NF, Bozic B, Pruijn GJ, Heck AJ: 
Elevated levels of fibrinogen-derived endogenous citrullinated peptides in 
synovial fluid of rheumatoid arthritis patients. Arthritis research & therapy 2012, 
14(3):R114. 
165. Marietta EV, Murray JA, Luckey DH, Jeraldo PR, Lamba A, Patel R, Luthra HS, 
Mangalam A, Taneja V: Suppression of Inflammatory Arthritis by Human Gut-
Derived Prevotella histicola in Humanized Mice. Arthritis & rheumatology 2016, 
68(12):2878-2888. 
166. Amara K, Steen J, Murray F, Morbach H, Fernandez-Rodriguez BM, Joshua V, 
Engstrom M, Snir O, Israelsson L, Catrina AI et al: Monoclonal IgG antibodies 
generated from joint-derived B cells of RA patients have a strong bias toward 
citrullinated autoantigen recognition. The Journal of experimental medicine 2013, 
210(3):445-455. 
 
Thesis for doctoral degree (Ph.D
.)  2017
Vijay Joshua
A
ntibody-A
ssociated In
am
m
ation In and O
utside the Joint in Rheum
atoid A
rthritis    
